<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2958947-A1" country="EP" doc-number="2958947" kind="A1" date="20151230" family-id="51390402" file-reference-id="276028" date-produced="20180825" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="160453320" ucid="EP-2958947-A1"><document-id><country>EP</country><doc-number>2958947</doc-number><kind>A1</kind><date>20151230</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-14753885-A" is-representative="NO"><document-id mxw-id="PAPP193869608" load-source="patent-office" format="original"><country>EP</country><doc-number>14753885.4</doc-number><date>20140220</date><lang>EN</lang></document-id><document-id mxw-id="PAPP193869609" load-source="docdb" format="epo"><country>EP</country><doc-number>14753885</doc-number><kind>A</kind><date>20140220</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC162036273" ucid="AU-2013900622-A" load-source="docdb"><document-id format="epo"><country>AU</country><doc-number>2013900622</doc-number><kind>A</kind><date>20130220</date></document-id></priority-claim><priority-claim mxw-id="PPC162028543" ucid="AU-2014000150-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>AU</country><doc-number>2014000150</doc-number><kind>W</kind><date>20140220</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1880656128" load-source="docdb">C08B  37/10        20060101AFI20161102BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1880656129" load-source="docdb">C08B  37/08        20060101ALI20161102BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1880656130" load-source="docdb">A61P  19/04        20060101ALI20161102BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1880656131" load-source="docdb">A61P  19/02        20060101ALI20161102BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1880656132" load-source="docdb">A61K  31/738       20060101ALI20161102BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1777709806" load-source="docdb" scheme="CPC">A61K  47/61        20170801 LI20170802BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1777709807" load-source="docdb" scheme="CPC">A61K  47/55        20170801 LI20170802BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1984697544" load-source="docdb" scheme="CPC">A61K  31/737       20130101 LI20160107BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1984700339" load-source="docdb" scheme="CPC">A61K  31/728       20130101 LI20160107BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1984702380" load-source="docdb" scheme="CPC">C08B  37/0072      20130101 FI20160108BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1984702391" load-source="docdb" scheme="CPC">A61K  45/06        20130101 LI20160107BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1984703630" load-source="docdb" scheme="CPC">C08B  37/0057      20130101 LI20160107BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1984704392" load-source="docdb" scheme="CPC">A61K  35/12        20130101 LI20160107BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987768160" load-source="docdb" scheme="CPC">A61K  35/32        20130101 LI20150331BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987779876" load-source="docdb" scheme="CPC">A61K  35/28        20130101 LI20150331BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT165551426" lang="DE" load-source="patent-office">KONJUGATVERBINDUNG UND VERWENDUNGEN DAVON</invention-title><invention-title mxw-id="PT165551427" lang="EN" load-source="patent-office">CONJUGATE COMPOUND AND USES OF SAME</invention-title><invention-title mxw-id="PT165551428" lang="FR" load-source="patent-office">COMPOSÉ CONJUGUÉ ET APPLICATIONS ASSOCIÉES</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR1103309730" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>UNIV QUEENSLAND</last-name><address><country>AU</country></address></addressbook></applicant><applicant mxw-id="PPAR1103337798" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>THE UNIVERSITY OF QUEENSLAND</last-name></addressbook></applicant><applicant mxw-id="PPAR1101650614" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>The University of Queensland</last-name><iid>101275408</iid><address><city>St.Lucia, Queensland 4072</city><country>AU</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR1103333218" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>JUSTIN COOPER-WHITE</last-name><address><country>AU</country></address></addressbook></inventor><inventor mxw-id="PPAR1103312736" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>JUSTIN, Cooper-White</last-name></addressbook></inventor><inventor mxw-id="PPAR1101645734" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>JUSTIN, Cooper-White</last-name><address><street>Lot 3 910 Upper Brookfield Road</street><city>Upper Brookfield, Queensland 4069</city><country>AU</country></address></addressbook></inventor><inventor mxw-id="PPAR1103316664" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>GHOSH PETER</last-name><address><country>AU</country></address></addressbook></inventor><inventor mxw-id="PPAR1103312219" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>GHOSH, PETER</last-name></addressbook></inventor><inventor mxw-id="PPAR1101645537" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>GHOSH, PETER</last-name><address><street>55 Collins Street, Level 39</street><city>Melbourne, Victoria</city><country>AU</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR1101652901" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Kohler Schmid Möbus</last-name><iid>100060092</iid><address><street>Partnerschaftsgesellschaft mbB Ruppmannstraße 27</street><city>70565 Stuttgart</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="AU-2014000150-W"><document-id><country>AU</country><doc-number>2014000150</doc-number><kind>W</kind><date>20140220</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2014127418-A1"><document-id><country>WO</country><doc-number>2014127418</doc-number><kind>A1</kind><date>20140828</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS660715575" load-source="docdb">AL</country><country mxw-id="DS660792667" load-source="docdb">AT</country><country mxw-id="DS660715577" load-source="docdb">BE</country><country mxw-id="DS660718319" load-source="docdb">BG</country><country mxw-id="DS660746885" load-source="docdb">CH</country><country mxw-id="DS660638828" load-source="docdb">CY</country><country mxw-id="DS660792668" load-source="docdb">CZ</country><country mxw-id="DS660725309" load-source="docdb">DE</country><country mxw-id="DS660715578" load-source="docdb">DK</country><country mxw-id="DS660638829" load-source="docdb">EE</country><country mxw-id="DS660635198" load-source="docdb">ES</country><country mxw-id="DS660718320" load-source="docdb">FI</country><country mxw-id="DS660718321" load-source="docdb">FR</country><country mxw-id="DS660715583" load-source="docdb">GB</country><country mxw-id="DS660715584" load-source="docdb">GR</country><country mxw-id="DS660715585" load-source="docdb">HR</country><country mxw-id="DS660792669" load-source="docdb">HU</country><country mxw-id="DS660746886" load-source="docdb">IE</country><country mxw-id="DS660715586" load-source="docdb">IS</country><country mxw-id="DS660718322" load-source="docdb">IT</country><country mxw-id="DS660638830" load-source="docdb">LI</country><country mxw-id="DS660725310" load-source="docdb">LT</country><country mxw-id="DS660792670" load-source="docdb">LU</country><country mxw-id="DS660725327" load-source="docdb">LV</country><country mxw-id="DS660725328" load-source="docdb">MC</country><country mxw-id="DS660636644" load-source="docdb">MK</country><country mxw-id="DS660636645" load-source="docdb">MT</country><country mxw-id="DS660792671" load-source="docdb">NL</country><country mxw-id="DS660715591" load-source="docdb">NO</country><country mxw-id="DS660792672" load-source="docdb">PL</country><country mxw-id="DS660715592" load-source="docdb">PT</country><country mxw-id="DS660792673" load-source="docdb">RO</country><country mxw-id="DS660725330" load-source="docdb">RS</country><country mxw-id="DS660792674" load-source="docdb">SE</country><country mxw-id="DS660725335" load-source="docdb">SI</country><country mxw-id="DS660638839" load-source="docdb">SK</country><country mxw-id="DS660638840" load-source="docdb">SM</country><country mxw-id="DS660636646" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>ME</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA139081611" ref-ucid="WO-2014127418-A1" lang="EN" load-source="patent-office"><p num="0000">Conjugate compounds of hyaluronic acid bonded to pentosan poiysulfate, or salts or derivatives thereof, are shown to induce chondrogenic differentiation of a population of mesenchymal stem celis as observed by, amongst other indications, increased glycosaminogSycan (GAG) production.</p></abstract><abstract mxw-id="PA139547938" ref-ucid="WO-2014127418-A1" lang="EN" source="national office" load-source="docdb"><p>Conjugate compounds of hyaluronic acid bonded to pentosan poiysulfate, or salts or derivatives thereof, are shown to induce chondrogenic differentiation of a population of mesenchymal stem celis as observed by, amongst other indications, increased glycosaminogSycan (GAG) production.</p></abstract><abstract mxw-id="PA139081612" ref-ucid="WO-2014127418-A1" lang="FR" load-source="patent-office"><p num="0000">La présente invention concerne des composés conjugués d'acide hyaluronique liés à du polysulfate de pentosane, ou ses sels ou dérivés, dont il a été démontré qu'ils induisent une différenciation chondrogénique d'une population de cellules souches mésenchymateuses, comme le montre, entre autres indications, l'augmentation de la production de glycosaminoglycanes (GAG).</p></abstract><abstract mxw-id="PA139547939" ref-ucid="WO-2014127418-A1" lang="FR" source="national office" load-source="docdb"><p>La présente invention concerne des composés conjugués d'acide hyaluronique liés à du polysulfate de pentosane, ou ses sels ou dérivés, dont il a été démontré qu'ils induisent une différenciation chondrogénique d'une population de cellules souches mésenchymateuses, comme le montre, entre autres indications, l'augmentation de la production de glycosaminoglycanes (GAG).</p></abstract><description mxw-id="PDES78478684" ref-ucid="WO-2014127418-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> CO JUGATE COMPOUND AND USES OF SAME </p><p id="p0002" num="0002">FIELD OF THE INVENTION </p><p id="p0003" num="0003">[00011 The invention relates to the field of medical treatment. More particularly, this invention relates to a novel conjugate compound and its use in treating or prsventsng a disease or condition responsive to connective tissue repair and/or maintenance. </p><p id="p0004" num="0004">BACKGROUND TO THE INVENTION </p><p id="p0005" num="0005"> [0002] Any reference to background art herein is not to be construed as an admission that such art constitutes common general knowledge in Australia or elsewhere. </p><p id="p0006" num="0006"> [0003] Adult mesenchymal stem ceils ( SCs) ere an abundant source of self-renewing, multipotent undifferentiated cells that can be readily Isolated from bone marrow, adipose tissue, muscle and synovium, and expanded In ex vivo culture. The ability of these cells to differentiate into bone, cartilage, adipose, tendon and other cells of the mesenchymal lineage under appropriate stimuli offers the potential for the regeneration and repair of the musculoskeletal system by their direct application to sites of injury [1 -3} or by their incorporation into bioscaffolds and transplantation into the sites of the tissue defect [1,4,5]. </p><p id="p0007" num="0007"> [0004] Stromal tissue in the bone marrow consists of a heterogeneous population of MSCs that occupy a perivascular niche. Studies have provided evidence for the existence within this niche of smaller precursor stem cell populations that exhibit extensive proliferative and muitilineage dlfferentiative capacity and can be distinguished by their expression of certain cell surface antigens [8,?]. These undifferentiated mesenchymal precursor cells ( PCs) can he isolated from bone marrow aspirates using techniques such as magnetic activated ceil sorting in combination with antibodies that identify STRO-1 , VCAM-1 (CD1Q6), STRO-3 (tissue nonspecific alkaline phosphatase), STRG-4 (HSP'-SOb) and CD146 [6,7]. 
<!-- EPO <DP n="3"/>-->
 [0005J Using this approach, a homogeneous population αί quiescent MPCs can be obtained that lack the phenotypic characteristics of leukocytes and mature stromal elements and exhibit extensive proliferative capacity whi!e retaining the ability to differentiate info bone, cartilage and adipose tissues. </p><p id="p0008" num="0008"> [0008] WO 2009/018813 in the name of Angioblasi Systems Inc disclosed the use of MPCs in treating diseases with an underlying etiology of inflamed or degraded connective tissue such as, for example, degenerative cervical and lumbar disc conditions. The inira-artlcular administration of MPCs was described as providing a chondroprotective effect in joints with pre-existing osteoarthritis and was found to lead to the growth of cartilage tissue in synovial joints and the nucleus pulposus of intervertebral discs. </p><p id="p0009" num="0009"> [0007j Ghosh et al [8] demonstrated that the presence of the semi-synthetic sulphated polysaccharide, pentosan poiysuifafe (PPS), induced the in vrtro proliferatio and chondrogenic differentiation of MPCs even absent the addition of growth factors or other chondroinductive supplements. It was postulated that a treatment regime combining PPS with Cs could benefit patients requiring repair and reconstitution of injured and degenerate cartilaginous tissues. The specificity of PPS as a promoter of chondrogenesss and the unpredictability of the success of other polysaccharides was demonstrated by the fact that dextran sulphate and heparin did not show any success in this role while hyaluronan showed some stimulation of MPCs to synthesise proteoglycan (PG) when present at low concentrations but at higher concentrations actually inhibited PG synthesis,</p><p id="p0010" num="0010">0008] The use of MPCs, with or without a promoter such as PPS, opens up a wide range of potential treatment methodologies to address diseases or conditions resulting from degradation of cartilaginous tissues, intervertebral disc ijVD) degeneration is just such a condition which can cause great discomfort and reduce quality of life significantly for a sufferer. Current treatments include immobilization and surgical intervention. Neither approach actually repairs the underlying tissue degeneration and recurrence of symptoms is likely. 
<!-- EPO <DP n="4"/>-->
 [0009] MPCs thus present the possibility of a new treatment paradigm. However, their use will require both effective delivery and careful control of the chemical and physical cues provided to ensure appropriate differentiation to provide regenerated or repaired tissue. </p><p id="p0011" num="0011">OBJECT OF THE INVENTION </p><p id="p0012" num="0012"> [0010] It is an aim of this invention to provide for a conjugate compound suitable for treating a condition responsive to connective tissue repair and/or maintenance which overcomes or ameliorates one or more of the disadvantages or problems described above., or which at least provides a useful alternative. </p><p id="p0013" num="0013"> [0011] Other preferred objects of the present invention will become apparent from the following description. </p><p id="p0014" num="0014">SUMMARY OF- INVENTION </p><p id="p0015" num="0015"> [0012] According to a first aspect of the invention, there is provided a conjugate compound comprising hyaluronic add, or a salt or derivative thereof, bonded to pentosan polysulfate, or a salt or derivative thereof. </p><p id="p0016" num="0016">[0013] Preferably, the hyaluronic acid and pentosan polysulfate are covalently bonded. </p><p id="p0017" num="0017"> [0014] Suitably, the conjugate compound is of formula HA-L-PPS wherein HA is hyaluronic acid, or a sail or derivative thereof, PPS Is pentosan polysulfate, or a salt or derivative thereof, and L is a linker unit having a first reactive group reactive with a first complimentary group on hyaluronic acid and further having a second reactive group reactive with a second complimentary group on pentosan<sup>'</sup> polysulfate. </p><p id="p0018" num="0018"> [0015] Preferably, L has a first reactive group reactive with a carbonyi or hydroxy! functional group on hyaluronic acid. </p><p id="p0019" num="0019"> [0016] Suitably, L has a second reactive group reactive with a carboxylic acid group on pentosan polysulfate. 
<!-- EPO <DP n="5"/>-->
 [0017] Preferably, the first and second reactive group are selected from the group consisting of - ί·½, OH and SH. </p><p id="p0020" num="0020"> [0018] in one embodiment, the conjugate compound of the first aspect is a conjugate compound of forrnuia {!), or a salt thereof: </p><p id="p0021" num="0021"><img id="imgf000005_0001" he="58" wi="83" file="imgf000005_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0022" num="0022">Formula (i) </p><p id="p0023" num="0023"> wherein, n <sub>?</sub> is sufficient to provide a molecular weight of between 1 ,000 to 20,000 daltons for the pentosan poiysulfate component of the conjugate and tt2 is sufficient to provide a molecular weight oi between 5,000 to 20,000,000 daltons for the hyaluronic acid component of the conjugate; </p><p id="p0024" num="0024"> each X is independently a sait forming ion seiected from the group consisting of sodium, calcium , magnesium and potassium ions OR X may be seiected from hydrogen, aikyi, alkenyl, carhoxyi, alkanoyi, alkanoyloxy and carboalkoxy; </p><p id="p0025" num="0025"> each Ri group is independently selected from a salt forming ion, hydrogen, alkyl, alkenyl, aryla!kyl, hydroxyaikyi, aldehyde, aikanone, earboxyi, earboxamide, alkanoyi, carboalkoxy, carboaryloxy, carbonate, O-alkyl, O-aryi, O-alkenyl, O-aikanoy! and O-alkenayl; and </p><p id="p0026" num="0026"> L is a linker unit as described above. 
<!-- EPO <DP n="6"/>-->
 [0019] Preferably, n-i is sufficient to provide a molecular weight of between 2000 to 10,000 dailons, more preferably 4000 to SOOO, for the pentosan polysulfate component of the conjugate. </p><p id="p0027" num="0027"> [0020] Preferably, r¾ is sufficient to provide a molecular weight of between 50,000 daitons to 2,000,000 daitons, more preferably between 100,000 daitons to 500,000 daitons for the hyaiuronic acid component of the conjugate. </p><p id="p0028" num="0028"> [0021] Preferably, L is F¾ which is selected from aikyi, aminoaikyi, diaminoaikyl, acyi, ether each of which may contain one or more further heteroatoms selected from sulphur, oxygen and nitrogen </p><p id="p0029" num="0029"> [0022] in one preferred embodiment the conjugate compound of formula (S) is a conjugate com ound of formula .(H), or a salt thereof: </p><p id="p0030" num="0030"><img id="imgf000006_0001" he="61" wi="83" file="imgf000006_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0031" num="0031"> Formula (II) </p><p id="p0032" num="0032"> wherein X, Ri, rti and n<sub>2</sub> are as already described and wherein. </p><p id="p0033" num="0033"> F¾ is selected from a!kyl, disulphide, a!kyfdisu!phide, acyi, ether, .carboalkoxy and alkanoyloxy. </p><p id="p0034" num="0034"> [0023] in one highly preferred embodiment the conjugate compound of formula (1) is a conjugate compound of formula (ill), or a salt thereof: 
<!-- EPO <DP n="7"/>-->
 
<img id="imgf000007_0001" he="64" wi="82" file="imgf000007_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0035" num="0035"> Formula (Iti) </p><p id="p0036" num="0036"> wheresn η¾ and r¾ and X are as already described. </p><p id="p0037" num="0037"> Preferably, X Is sodium.</p><p id="p0038" num="0038">00241 in a further highly preferred embodiment the conjugate compound of formula i) is a conjugate compound of formula (ilia), or a salt thereof: </p><p id="p0039" num="0039"><img id="imgf000007_0002" he="63" wi="95" file="imgf000007_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0040" num="0040"> wherein η-, and η<sub>2</sub> are as defined above. </p><p id="p0041" num="0041"> 10025] According to a second aspect of the invention there is provided a method oi syninesising a conjugate compound of the first aspect Including the 
<!-- EPO <DP n="8"/>-->
 step of coupling hyaluronic acid, or a derivative thereof, to pentosan poiysuffate, or a derivative thereat via a covalent bond. </p><p id="p0042" num="0042"> [0028] Preferably, the hyaluronic acid or pentosan poiysuipnate, or a sait or derivative thereof, are first chemicaliy modified to present a !inker unit prior to covaient bonding. </p><p id="p0043" num="0043"> [0027] Suitably, the hyaluronic acid, or sait or derivative thereof, is chemically modified to present a linker group having a primary amine functionality. </p><p id="p0044" num="0044"> [0028] Preferably, the chemical modification of the hyaluronic acid, or salt or derivative thereof, is performed via a carboxyi group activation pathway using a carboxyi activating group. Preferably, the carboxyi activating group is an imide, more preferably it is a carfoodii ide such as 1~ethyi~3-(.¾-dimethylaminop?Opyl) carbodlimide (EDC), andior a succinimide such as Λ/'hydroxysuccsnimide ester,</p><p id="p0045" num="0045">{00291 Suitably, the primary amine of the hyaluronic acid !inker group is reacted with a carboxyi group on the pentosan polysuifate, or salt or derivative thereof. </p><p id="p0046" num="0046"> [0030] A third aspect of the invention resides in a conjugate compound produced by the method of the second aspect. </p><p id="p0047" num="0047"> [0031] According to a fourth aspect of the invention there is provided a pharmaceutical composition comprising an effective amount of a conjugate compound of the first or third aspect, or a pharmaceutically acceptable salt thereof, and a pharmaceuticaliy acceptable carrier, diluent and/or excipient. </p><p id="p0048" num="0048">[0032] Suitably, the pharmaceutical composition is for the treatment or prophylaxis of a diseass, disorder or condition responsive to connective tissue repair and/or maintenance, such as connective tissue degeneration. </p><p id="p0049" num="0049">[0033] in one embodiment, the pharmaceutical composition further comprises piuripotent or multipotent stem cet!s. in one particular embodiment, the pharmaceutical composition may take the form of a polymeric matrix within 
<!-- EPO <DP n="9"/>-->
 which the conjugate compound of the first or third aspect and a multipotent stem eel! population are located. Preferably, the polymeric matrix is a hydrogei. </p><p id="p0050" num="0050"> [0034] The pharmaceutical composition may comprise further additives selected from the group consisting of glycosaminoglycan (GAG), unbound hyaluronic acid (HA), chondroitin sulphate, dermatan sulphate, keratin sulphate, heparin, heparin sulphate and unbound PPS. </p><p id="p0051" num="0051"> [0035] A fifth aspect of the invention resides in a method of treating or preventing a disease, disorder or condition responsive to connective tissue repair and/or maintenance in a patient including the step of administering an effective amount, of a conjugate compound of the first or third aspect and pluripotent or rnuitipotent stem cells, and/or progeny cells thereof, or the pharmaceutical composition of the fourth aspect to the affected or potentiall affected tissue. </p><p id="p0052" num="0052"> [0036] In one embodiment, the disease, disorder or condition is connective tissue degeneration. Preferably, the affected tissue is an intervertebral disc, a cartilaginous structure, such as a meniscus, or bone tissue. </p><p id="p0053" num="0053"> [0037] The conjugate compound and multipotent stem cells may be coadministered. Preferably, the conjugate compound and multipotent stem cells are administered within a polymeric matrix, such as a hydrogei. </p><p id="p0054" num="0054"> [0038] The multipotent stem cells may be selected from the group consisting of mesechymai precursor cells (MFCs), dental pulp stem ceils (DPSCs) and periodontal ligament stem ceils (PDLSCs). </p><p id="p0055" num="0055"> [0039] Preferably, the muitipotent stem cells are MPGs. in one embodiment, the MPCs are STRO-1 * PCs. In a particular embodiment the MPCs are obtained or are obtainable from human bone marrow, </p><p id="p0056" num="0056"> [0040] The method may also include administering further additives selected from the group consisting of glycosaminoglycan {GAG}, unbound hyaluronic acid (HA), chonda-Jitin sulphate, dermatan sulphate, keratin sulphate, heparin, heparin sulphate and unbound PPS. 
<!-- EPO <DP n="10"/>-->
 [0041 ] A sixth aspect of the invention provides for a conjugate compound of the first orthird aspect, or a pharmaceutical acceptable salt thereof, for use in the treatment or prophylaxis of a disease, disorder or condition responsive to connective tissue repair and/or maintenance in a patient. </p><p id="p0057" num="0057"> [0042] A seventh aspect of the invention resides in a method of enhancing, promoting or maintaining the chondrogenic potential of a stem ceil inciuding the step of contacting the stem ceil with the conjugate compoun of the first or third aspect. The stern ceil may be selected from the group consisting of MPCs DPSCs and PDLSCs. </p><p id="p0058" num="0058"> [0043] An eighth aspect of the invention resides in a method of reducing or inhibiting the osteogenic differentiation of a stem ceii inciuding the step of contacting the stem ceii with the conjugate compound of the first or third aspect. The stem ceil may be selected from the group consisting of MFCs, DPSCs and PDLSCs. </p><p id="p0059" num="0059"> [0044] A ninth aspect of the invention resides in the use of the conjugate compound of the first or third aspects in the manufacture of a medicament for the treatment or prophylaxis of a disease, disorder or condition responsive to connective tissue repair and/or maintenance, </p><p id="p0060" num="0060"> [0045] The various features and embodiments of the present invention, referred to in individual sections above apply, as appropriate, to other sections, mutatis mutandis. Consequently features specified in one section may be combined with features specified in other sections as appropriate. </p><p id="p0061" num="0061"> [0046] Furthe features and advantages of the present invention will become apparent from the following detailed description. </p><p id="p0062" num="0062">BRIEF DESCRiPTiON OF THE DRAWINGS </p><p id="p0063" num="0063"> [0047] In order that the invention may be readily understood and put into practical effect, preferred embodiments will now be described by way of example with reference to the accompanying figures wherein: 
<!-- EPO <DP n="11"/>-->
 [0048] FIG 1 is a reaction scheme for the funciionaiisation of HA to present a linker unit; </p><p id="p0064" num="0064"> [Q049] FIG 2 shows reaction schemes representing the synthesis of HARPS and HA-PPScooM using the funetionalised HA of FIG 1 ; </p><p id="p0065" num="0065"> [0050] FIG 3 is an attenuated total reflectance-Fourier transform infrared (ATR-FT!R) spectrum indicating the carboxy funciionaiisation of PPS; </p><p id="p0066" num="0066"> [0051] FIG 4A is an ATR-FTI spectrum showing the amine functionalisation of HA; </p><p id="p0067" num="0067"> [0052] FIG 4B is a graphical representation of the amine group content of various species; </p><p id="p0068" num="0068"> [0053] FIG 5A is a proton NMR spectrum of HA-PPS; </p><p id="p0069" num="0069"> [0054] FIG 5B is a proton NMR spectrum of HA-PPSCOOH; </p><p id="p0070" num="0070"> [0055] FIG 6 is a graphical representation of the results of a CC 8 assay indicating proliferation of MPCs when treated with conjugate compounds of the invention and controls; </p><p id="p0071" num="0071"> [0058] FIG 7 is a series of graphical representations of the gene expression of MFCs which have been treated with the conjugate compounds of the invention; </p><p id="p0072" num="0072"> [0057] FiG 8A is an Alizarin stain of human SCs indicating mineralisation relative to controls in the presence of a conjugate compound of the invention and with and without addition of BMP-8; </p><p id="p0073" num="0073"> [0058] FIG 88 is an ALP stain of human MSCs indicating alkaline phosphatise levels relative to controls in the presence of a conjugate compound of the invention and with and without addition of BMP-8; </p><p id="p0074" num="0074"> [0059] FIG 8C is a graphical representation of the ALP activity relative to the DNA content of cells (as determined by pNPP assay); </p><p id="p0075" num="0075"> [0060] FIG 9A Is a graphical representation of the GAG expression of chondrogensc MFCs after treatment with the conjugate compounds of the invention in the absence of additional chondrogensc initiating factors; 
<!-- EPO <DP n="12"/>-->
 [0081] FIG QB shows a series of histological sections of the chondrogenic pellet MFCs; </p><p id="p0076" num="0076"> Ϊ0062] FiG 10A is a graphical representation of the swelling profile of a HA/PEG hydrogel incorporating PPS and HA-PPS; </p><p id="p0077" num="0077"> [0063] FIG 10B Is a graphicai representation of the degradation profile of a HA/PEG hydrogel incorporating PPS and HA-PPS; </p><p id="p0078" num="0078"> [0064] FIG 1 1 is a series of images showing the viability of MFCs when encapsulated in a HA/PEG hydrogel incorporating PPS and HA-PPS; </p><p id="p0079" num="0079"> [0065] FIG 12 is a series of histological stains indicating the structure and composition of MPC/hydrogel composites; </p><p id="p0080" num="0080"> [0066] FSG 13 Is a series of stains of MPC/hydrogel composites for collagen-ll deposition; and </p><p id="p0081" num="0081"> [0067) FiG 14 Is a series of graphical representations indicating the expression of various factors by MFCs encapsulated within a HA/PEG hydrogel incorporating HA-PPS. </p><p id="p0082" num="0082"> DETAILED DESCRIPTION </p><p id="p0083" num="0083"> [0068] The present invention is predicated, at least in part, on the finding that a conjugate compound of hyaluronic acid bonded to pentosan po!ysuifaie, or salts or derivatives thereof, can induce chondrogenic differentiation of a population of fviPCs as observed b increased, amongst other indications, giycosaminogiycan (GAG) production. The GAG expression observed for two different conjugate compounds of the invention were each significantly greater than that seen when PPS alone was present. This result is surprising as exposure of IvSPCs to HA alone did not produce any increase in GAG production and so the combination of HA and PPS (or a PPS derivative) in a conjugate compound cou!d not have been predicted to produce such an increase in GAG production over PPS alone. </p><p id="p0084" num="0084"> Definitions 
<!-- EPO <DP n="13"/>-->
 [0069] in this patent specification, adjectives such as first and second, left and right,, front and back, tap and bottom, etc, are used solely to define one element or method step from another element or method step without necessarily requiring a specific relative position or sequence that is described by the adjectives. The terms 'comprises', 'comprising', includes<sup>'</sup>, 'including', or similar terms are intended to mean a non-exciusive inclusion, such that a method, system or apparatus that comprises a list of elements does not include those elements solely, hut may well include other elements not listed. </p><p id="p0085" num="0085"> [0070] Unless defined otherwise, ail technical and scientific terms used herein have the same meaning as would be commonly understood by those of ordinary skill in the art to which this invention belongs, </p><p id="p0086" num="0086"> [0071] As used herein, and unless the nature of t e bonding is specified, the terms "bond", "bonding" and "bonded" refer generally to an attraction or association between hyaluronic acid and pentosan polysulfafe which may take the form of covatent bonding, ionic bonding, hydrogen bonding interactions or other weak electrostatic interactions. </p><p id="p0087" num="0087"> [0072] The term "conjugate, compound", as used herein, refers to a compound formed by the joining of a number of separate compounds. Particularly, the term is used herein to describe a compound formed by the joining, preferably by covalent bonding, of two separate polysaccharide molecules. Specifically, the term is used to describe a compound formed by the bonding, preferably covalent bonding, of HA and PPS or salts or derivatives of each. </p><p id="p0088" num="0088"> [0073] As used herein, the term "derivative", particularly in relation to hyaluronic acid or pentosan polysuifate, refers to a closely related compound to the named compound in which the existing functional groups of the named compound have been modified or transformed to provide a different functionality while the core skeleton of the compound remains unchanged. Functional group modifications or transformations contemplated are those which are standard in the art. As one non-limiting example, the conjugate compound of formula (ilia) is formed by the reaction of HA with a PPS 
<!-- EPO <DP n="14"/>-->
 derivative whereby the sulfate ester groups of standard PPS have been modified to present carboxylic acid groups. This carboxyi modified PPS is considered to be a derivative of PPS. References herein to HA and PPS are considered to include their sails and/or derivatives. </p><p id="p0089" num="0089"> [0074] In certain embodiments the derivative of PPS may be selected from the group consisting of alkyi, afkenyl, carboxyi, afkanoy!, aikanoyloxy, carboalkoxy derivatives and salts such as sodium, calcium , magnesium and potassium salts thereof. The alkyi, a!ken l, carboxyi, alkanoy!, aikanoyloxy and carboaikoxy groups may be as defined hereinafter. </p><p id="p0090" num="0090"> [0075] in certain embodiments the derivative of HA may be selected from the grou consisting of alkyi. alkenyl, arylalk<sup>'</sup>yl, hydroxyalkyi, aldehyde, atkanone, carboxyi, carboxamide, alkanoyl, carboalkoxy, carboaryioxy, carbonate, Oaikyl, Q-aryl, Q-alkenyl, O-alkanoyl and O-alkenoyi derivatives and salts such as sodium, calcium , magnesium and potassium salts thereof. The alkyi and other functional groups recited In this paragraph are as defined hereinafter. </p><p id="p0091" num="0091"> [0076] Derivatives of the compounds or conjugate compounds described herein can be obtained by techniques known in the art. For example, hydroxy groups may be oxidised, to ketones, aldehydes or carboxylic acids by exposure to oxidising agents such as chromic acid, Jones' reagent, potassium permanganate (KMnG*), peracids such as metachloroperbenzoic acid (mCPBA) or dioxiranes such as dimeihykiioxirane (D DO) and methyl(trif!uoromethyf)dioxifane (TFDO). Oxidising agents may be chosen such that other functional groups in the molecule are, or are not, also oxidised. For example, a primar alcohol may be selectively oxidised to an aldehyde or carboxylic acid in the presence of secondar alcohols using reagents such as RuCfe(PPh3)3-faenzene. Secondary alcohols may be selectively Oxidised to ketones in the presence of a primary alcohol using Ci<sub>;r</sub>pyndine or NaBrOj-ceric- ammoniom nitrate. Alcohols may be oxidised in the presence of double and triple bonds and without epimerisaiion at adjacent stereocentres using Jone's reagent. Alternatively, reagents chosen may be less selective resulting in 
<!-- EPO <DP n="15"/>-->
 oxidation at more than one functional group. A person skilted in the art is be able to determine suitable conditions for obtaining derivatives of isolated compounds, for example, by reference to texts relating to synthetic methodology, non-limiting examples of which are Smith M.S. and March J., March's Advanced Organic Chemistry, Fifth Edition, John Wiley &amp; Sons Inc., 2001 and Laroek R,C, Comprehensive Organic Transformations, VCH Publishers Ltd., 1989. Furthermore, selective manipulations of functional groups may require protection of other functional groups. Suitable protecting groups to prevent unwanted side reactions are provided in Green and VVuts, Protective Groups in Organic Synthesis, John Wiley &amp;. Sons Inc., 3rd Edition, 1899. </p><p id="p0092" num="0092"> [0077] As used herein, "effective amount" refers to the administration of an amount of the relevant active agent sufficient to prevent the occurrence of symptoms of the condition being treated, or to bring abou a halt in the worsening of symptoms or to treat and alleviate or at least reduce the severity of the symptoms The effective amount will vary in a manner which would he understood by a person of skill in the art with patient age, sex, weight etc. An appropriate dosage or dosage regime can be ascertained through routine trial. </p><p id="p0093" num="0093"> [0078] The term "piuripotent stem cells" or "muitipotent stem cells" as used herein refers to a population of cells which can proliferate and differentiate, info a plurality of different cell lineages. Multipotent stem ceils may be of adult or embryonic origin. Preferably, they are of adult origin, </p><p id="p0094" num="0094"> [0079] In preferred embodiments the muiiipotent stem cells include mesenchymal precursor cells (MFCs), dental pulp stem cells {DPSCs} and periodontal ligament stem cells (PDLSCs), Both DPSCs and PDLSCs are known to be capable of differentiation into a number of cell types including chondrocytes and osteocytes. MFCs are typically undifferentiated cells that can be isolated from bone marrow and are characterized, at least partly, by the expression of cell surface markers such as STRO-1 , VCA -1 (CD106), STRO- 3 (tissue nonspecific alkaline phosphatase), STRO-4 (HSP-90b) and CD1 6. in one embodiment, the MFCs are STRO-1 <sup>*</sup> fvtPCs. In a particular embodiment, 
<!-- EPO <DP n="16"/>-->
 the MFCs are obtained or are obtainable from human bone marrow. Suitably, the STRO-1<sup>+</sup> MPCs may be selected and/or purified by antibody-mediated immunoseleciion. Non-limiting examples of immunoseleciion include flow cytometry, panning and magnetic bead selection, although without limitation thereto. The MSCs rnayfurther be derived from induced piuripotent stem ceils (diPSCs) by inhibition of the TGFp/activln signalling pathway. </p><p id="p0095" num="0095"> [0080] The term "pharmaceutically acceptable salt", as used herein, refers to salts which are toxicologlcaliy sets for systemic or localised administration such as salts prepared from pharmaceutically acceptabie non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. The pharmaceutically acceptable saits may be selected from the group including alkali and alkali earth, ammonium, aluminium, iron, amine, glucosamine, chloride, sulphate, su!phonate, blsuSphate, nitrate, citrate, tartrate, bi arate, phosphate, carbonate, bicarbonate, malate, maieate, napsyiate, fumarate, succinate, acetate, benzoate, terepbtha!ate, palmoate, piperazine, pectinate and S-meihyi methionine .salts and the like. </p><p id="p0096" num="0096"> [0081 ] The term "aikyt refers to optionally substituted linear and branched hydrocarbon groups having 1 to 20 carbon atoms inclusive of 1 to 16 carbon atoms, 1 to 14 carbon atoms, 1 to 12 carbon atoms, 1 to 10 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms and 1 to 4 carbon atoms. Where appropriate, the alky! group may have a specified number of carbon atoms, for example, C Cs alkyi which includes aikyi groups having 1, , 3, 4, 5 or 6 carbon atoms in linear or branched arrangements. Non-limiting examples of aikyi groups include methyl, ethyl, propyl, isopropyl, butyl, s- and t-butyi, pentyi, 2- methylbutyl, 3-methyibutyi, hexyl, heptyl. 2-methylpentyl, 3-methySpenlyl, 4- meihy!penty!, 2-ethy!bufyl, 3-efhylbutyl, ociyi, nonyl, decyi, undecyl, dodecyi, tridecy!, fetradecyl, pentadecyi. </p><p id="p0097" num="0097"> [0082] The term "e!keny refers to optionally substituted unsaturated linear or branched hydrocarbon groups, having 2 to 20 carbon atoms, inclusive of 1 to 16 carbon atoms, 1 to 14 carbon atoms, 1 to 12 carbon atoms, 1 to 10 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms and 1 to 4 car on atoms, and 
<!-- EPO <DP n="17"/>-->
 having at least one carbon-carbon doubie bond, Where appropriate, the aikenyl group may have a specified number of carbon atoms, for example, C C<sub>e</sub> aikenyl which includes aikenyl groups having 2, 3, 4, 5 or 8 carbon atoms ininear or branched arrangements. Non-limiting examples of alkenyl groups include, ethenyl propenyi, isopropenyi, butenyl, s- and t-buienyl, pentenyi, hexenyi, hept-!,3-dsene, hex-i<sub>(</sub>3-diene, non-l.3,S-triene and the like. The term "alkenyl" embraces substituents having "cis" and "trans" orientations, or alternatively, Έ" and "7." orientations. </p><p id="p0098" num="0098"> [0083] The term "atkanoyf refers to an acyi moiety of a straight or branched configuration having 1 to 20 carbon atoms, Inclusive of 1 to 18 carbon atoms, 1 to 14 carbon atoms, i to 12 carbon atoms, 1 to 10 carbon atoms. 1 to 8 carbon atoms, 1 to 6" carbon atoms and 1 to 4 carbon atoms. Examples of aikanoy! groups include, but are not limited to, acetyl, propionoy!, buiyryi, isobutyryl, pentano l and hexanoyi. </p><p id="p0099" num="0099"> |0084] The term "carboa!koxy" refers to an alky! ester of a carboxy!ic acid, wherein aikyi has the same definition as found above. Examples include carbometboxy, carfooethoxy, carboisopropoxy and the like. </p><p id="p0100" num="0100">f0085] The term "a!kanoyloxy" refers to an alkanoyl group linked via an oxygen bridge wherein the alky! portion of the alkanoyl moitey may be as described above. </p><p id="p0101" num="0101"> [0086] The term "ar f refers to an aromatic substitusnt containing one ring or two or three fused rings. The aryl substifueni may have six to eighteen carbon atoms, As an example, the aryl substrtuent may have six to fourteen carbon atoms. The term "aryl" may refer to substituents such as phenyl, naphthyl and anthracenyl. The term "aryi" also includes substituents such as phenyl, naphthyl and anthracenyl that are {used to a C4-C10 carbocyclic ring, such as a C5 or a C<sub>e</sub> carbocyclic ring, or to a 4-10-mernbered heterocyclic ring, wherein a group having such a fused aryi group as a substituent is bound to an aromatic carbon of the aryl group. When such a fused aryl group is substituted with one more substituents, the one or more substituents, unless otherwise specified, are each bound to an aromatic carbon of the fused aryl group. The 
<!-- EPO <DP n="18"/>-->
 fused C-C-io carbocyc!ic or 4-10-membered heterocyclic ring may be optionally substituted with halogen, C<sub>r</sub>C§ alkyf , C3-C1C cycloalkyl, or Examples of aryi groups include accordingly phenyl, naphthalenyl, tetrahydronaphthalenyl (also known as "tetralinyi"), indenyi. isoindenyi, indanyl, anthracenyl, phenanthreny!, henzonaphthenyi (also known as "phenaienyi"), and fluorenyl. </p><p id="p0102" num="0102"> [0087] The definitions just provided apply to related derivatives i.e. the definitions of alkyf, aikenyl etc provided above apply to the relevant portion of O-alkyl, Q-alkeny!, G-alkanoy! and other terms used herein as would bo understood by a person of sKli! in the art. </p><p id="p0103" num="0103"> [0088] As used herein, the terms "sub ect' or "individual* or "psti&amp;nf may refer to any subject, particularly a vertebrate subject, and even more particularly a mammalian subject, for whom therapy or prophylaxis is desired. Suitable vertebrate animals Include, but are not restricted to. primates, avians, livestock animals (e.g., sheep, cows, horses, donkeys, pigs), laboratory test animals (e.g., rabbits, mice, rats, guinea pigs, hamsters), companion animals (e.g., cats, dogs) and captive wild animals (e.g., foxes, doer, dingoes), A preferred subject Is a human In need of treatment or prophylaxis for a condition related to connective tissue degradation, particularly iVD degeneration. However, it will be understood that the aforementioned terms do not imply that symptoms ere necessarily present. </p><p id="p0104" num="0104"> Conjugate Compounds and Use Thereof </p><p id="p0105" num="0105"> [0089] Although the bulk of the following discussion addresses the use of a conjugate compound of HA-PPS to enhance the chondrogenic phenotyp of MFCs it will be appreciated that the invention is not so limited. The same conjugate compounds may be employed, mutatis mutandis, to control of the differentiation of other multipotent stem cell types including DPSCs, PDLSCs as well as with diPSCs. </p><p id="p0106" num="0106"> [0090] According to a first aspect of the invention, there is provided a conjugate compound comprising hyaluronic acid, or a salt or derivative thereof, bonded to pentosan polysuifate, or a salt or derivative thereof. The HA and PPS may be covalently bonded or bonded though electrostatic or other interactions, 
<!-- EPO <DP n="19"/>-->
 including ionic, dipois-dipole and hydrogen bonding. Whatever the bonding the HA and PPS will be strongly associated with one another to an extent substantia!!]/ greater than it they were simply present in solution together. This can achieved through means including adjustment of pH, controlling the concentration of the HA and PPS to be suitably high and trapping of the PPS within a HA polymeric matrix. </p><p id="p0107" num="0107"> [0091] Preferably, the hyaluronic acid and pentosan polysuifate are covalentiy bonded. </p><p id="p0108" num="0108"> [0082] Suitably, the conjugate compound Is of formula HA-L-PPS wherein HA is hyaluronic acid, or a salt or derivative thereof, PPS Is pentosan polysuifate, or a salt or derivative thereof, and L is a linker unit having a first reactive group reactive with a first complimentary group on hyaluronic acid and further having a second reactive group reactive with a second complimentary group on pentosan polysuifate. Linker chemistry is a weil developed field and a person skilled in the art of organic chemistry generally, and linker or coupling chemistry specifically, would be familiar with the available options to link HA and PPS. For example, unmodified HA presents carboxyl, alcohol and carbonyi functionalities while PPS presents carboxyl, a!koxy and sulphate ester moieties. Linker unfe can be chosen from a wide range available which have at least two functional groups, one to react with a HA functional group and the other to react with a PPS functional group, as both described above. Alternatively, one o more of the existing functional groups on HA and/or PPS may first undergo a functional group transformation to thereby present a more selective or reactive group for either subsequent reaction with the linker unit or direct reaction with the other of HA or PPS. </p><p id="p0109" num="0109"> [0093] Preferably, L has a first reactive group reactive with a carbonyi or hydroxy! functional group on hyaluronic acid. </p><p id="p0110" num="0110"> [0094] Suitably, L has a second reactive group reactive with a carhoxylie acid group on pentosan polysuifate, </p><p id="p0111" num="0111"> [0096] Preferably, the first and second reactive group are selected from the group consisting of -NH<sub>¾</sub>, OH and SH 
<!-- EPO <DP n="20"/>-->
 [0096] Preferably, I is a diamine. A wide range of bridging diamine linkers are commercially available such as. for exampie, cystamine. The diamine linker may take the form of two primary amine groups joined by a simple alky! chain of between 1 to 20 carbon atoms, inclusive of 1 to 16 carbon atoms, 1 to 14 carbon atoms, 1 to 12 carbon atoms, 1 to 10 carbon atoms, 1 to 8 carbon atoms, 1 to 8 carbon atoms and 1 to 4 carbon atoms. Alternatively, the chain may be branched and/or one of the amine groups may be presented from a branch of the main chain or the chain may present double or triple bonds. Further, the diamine linker may have a chain comprising one or more be eroatoms. The beteroatoms may be part of functionalities such as disulphide, thioether, ether, amide and others common in the art. </p><p id="p0112" num="0112"> [0097] In certain embodiments the HA may also present a further functionality suitable for cross linking to incorporate the HA, and bound PPS, into a hydrogel. The further functional group may be a hydroxy! group Including a phenolic or benzyl hydroxy! group. </p><p id="p0113" num="0113"> [0098] In one embodiment, the conjugate compound of the first aspect is a conjugate com ound of formula (I), or a salt thereof: </p><p id="p0114" num="0114"><img id="imgf000020_0001" he="60" wi="84" file="imgf000020_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0115" num="0115"> Formula (i) </p><p id="p0116" num="0116"> wherein, η·ι is sufficient to provide a molecular weight of between 1 ,000 to 20,000 daitons for the pentosan poiysulfate component of the conjugate and 
<!-- EPO <DP n="21"/>-->
 !¾ is sufficient to provide a molecular weight of between 5,000 to 20,000,000 daltons for the hyaluronic acid component of the conjugate. </p><p id="p0117" num="0117"> each X is independently a salt forming ion selected from the group consisting of sodium, calcium , magnesium and potassium ions OR X may be selected from hydrogen, alky!, a!kenyl, carboxyl, aikanoyi, aikanoytoxy and carboa!koxy; </p><p id="p0118" num="0118"> each i group is independentl selected from a salt forming ion, hydrogen, a!kyl, aikenyi, ary!aikyl, hydroxyalkyi, aldehyde, afkanone, carboxyl, earboxamide, aikanoyl, earboaJkoxy, car oaryloxy, carbonate, O-alkyl, O-aryl, O-alkenyi, Q-aikanoyl and O-aikenoyi; and </p><p id="p0119" num="0119"> L is a linker unit as previously described. </p><p id="p0120" num="0120"> [0099] Preferably, n ; is sufficient to provide a molecular weight of between 2000 to 10,000 daltons, more preferably 4000 daltons. to 8000 daltons, most preferably between 5000 daltons to 6000 Gallons for the pentosan poiysu!fate component of the conjugate. </p><p id="p0121" num="0121"> [00100] Preferably, t¾ is sufficient to provide a molecular weight of between 50,000 daltons to 2,000,000 daltons, more preferably between 100,000 daltons to 500,000 daltons, most preferably between 200,000 daltons to 250,000 daltons for the hyaluronic acid component of the conjugate. </p><p id="p0122" num="0122"> [001013 in one embodiment L is F¾ which is selected from alkyl, arrsinoa!kyi, diaminoaikyl, acyi, aryl, ether each of which may contain one or more further heteroatoms selected from sulphur, oxygen and nitrogen </p><p id="p0123" num="0123"> [00 02] The conjugate compound of formula (I) represents a covalentiy bonded conjugate of PPS, or a derivative thereof, represented by the structure within the bracket defined by n<sub>1</sub> , and HA, or a derivative thereof, as represented by the structure within the bracket defined by r¾. The skilled addressee will appreciate that the exact value of rv, and ¾ will vary based on the particular PPS and HA starting materials chosen. The molecular weight of the pentosan polysu!fate may differ between different manufacturers and, to some extent, even between different batches from the same manufacturer. Further, there is a 
<!-- EPO <DP n="22"/>-->
 wide range of commercially available HA products of different rnolecuiarweighl. it will also be appreciated that, in any event, the n values are simpiy weighted averages of the natural variation in molecular weights observed for such polysaccharide products. </p><p id="p0124" num="0124"> [00103] Further, PPS is a polysaccharide composed of repeating units of 1-4 linked heta-D-xylopyranose with substituted 4-methyigiucapyrariosyturonicacid units being presented,, on average, every tenth xylopyranose unit. It will therefore be understood that the structure shown in the formulae described herein, and the n values associated therewith, takes into account that the 4~ rneihylglucopyranosyiuronic acid is only present every tenth xylopyransose repeat unit although, for the sake of brevity, this has not been explicitly indicated in the structures shown. </p><p id="p0125" num="0125"> 100104] Further stiii, if wiil be understood that not every available carboxyl group of the HA or PPS will be involved in binding. Both HA and PPS are polymeric structures with relatively high molecular weights and so when they are funetionalised or bound together it is expected that oniy a portion of those available groups will actually participate in the reaction, The above points would be evident to a person of skill in the art upon reviewing the structures herein and wouid appreciate that they are best representations of the actual chemistry occurring. </p><p id="p0126" num="0126"> [00 05] in one preferred embodiment the conjugate compound of formula (I) is a conjugate compound of formula (!i), or a salt thereof: 
<!-- EPO <DP n="23"/>-->
</p><p id="p0127" num="0127"><img id="imgf000023_0001" he="60" wi="83" file="imgf000023_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0128" num="0128"> Formuia (11} </p><p id="p0129" num="0129"> wherein X. Ftj, n<sub>:</sub> and n<sub>3</sub> are as already described and wherein, 3 is selected from aikyf, disulphide, alkyldisulphide, acyi, ether, earboalkoxy and a!kanoyloxy. </p><p id="p0130" num="0130"> [00108] The HA component may present a further functional group at carboxyi groups not invoived in PPS binding, as discussed above. These will take part In cross iinking reactions with a further polymeric structure to incorporate the conjugate compound into a hydrogeS. </p><p id="p0131" num="0131"> [00107] in one highly preferred embodiment the conjugate compound of formula (1) is a conjugate compound of formula (111), or a salt thereof: 
<!-- EPO <DP n="24"/>-->
</p><p id="p0132" num="0132"><img id="imgf000024_0001" he="64" wi="82" file="imgf000024_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0133" num="0133"> Formula (Hi) </p><p id="p0134" num="0134"> wherein n&lt; and n<sub>¾</sub> and X are as already described. </p><p id="p0135" num="0135">[00108] Preferably, X is sodium. The conjugate compound of formula (ill) represents the conjugation of PPS, of which different saft forms are oommercialiy available, with HA in their unmodified form. References herein to the experimental use of HA-PPS can be taken as reference to a conjugate compound of formula (Hi) wherein X is sodium. As described above, unbound carboxyl groups of the HA may present a further functionality for hydrogei incorporation. </p><p id="p0136" num="0136"> [001 D91 in a further highly preferred embodiment the conjugate compound of formula (I) is a conjugate compound of formula (Ilia), or a salt thereof: 
<!-- EPO <DP n="25"/>-->
</p><p id="p0137" num="0137"><img id="imgf000025_0001" he="64" wi="94" file="imgf000025_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0138" num="0138"> Formula (Ilia) </p><p id="p0139" num="0139"> wherein n and ¾ are as defined above. </p><p id="p0140" num="0140"> [00110] The conjugate compound of formula (fiia) represents the conjugation of a modified PPS with HA in its unmodified form. Specifically, the PPS has been modified to present carboxyl groups by reaction at its sulphate ester moieties. This carboxyl modified PPS will be referred to herein as PPSCOOH an the conjugate compound of formula {Ilia} can be specifically referred to as HA- PPSCOOH- AS described above, unbound carboxyl groups of the HA may present a further functionality for hydrogef incorporation. </p><p id="p0141" num="0141"> [00111] According to a second aspect of the invention there is provided a method of synthesising a conjugate compound of the first aspect including the step of coupling hyaluronic acid, or a derivative thereof, to pentosan poi suifafe, or a derivative thereof, via a covalent bond, </p><p id="p0142" num="0142">j00112] Preferably, the hyaluronic acid and/or pentosan polysuiphate, or a salt or derivative thereof<sub>:</sub> are first chemically modified, as discussed above, to present a linker unit prior to covalent bonding. </p><p id="p0143" num="0143"> [00113] Suitably, the hyaluronic acid, or sa!t or derivative thereof, is chemically modified to present a linker group having a primary amine functionality. 
<!-- EPO <DP n="26"/>-->
 [00114] Preferably, the chemical modification of the hyaluronic acid, or salt o derivative thereof, is performed via a carboxy! group activation pathway using a carbox i activating group. Preferably, the carboxy! activating group is an smide, more preferably it is a carbodiimide such as 1 -ethy!~3-{3-dimethyiarninopropyi)
<img id="imgf000026_0001" he="5" wi="116" file="imgf000026_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </p><p id="p0144" num="0144"> [001 15] Suitably, the primary amine of the hyaluronic acid linker group is reacted with a carboxyi group on the pentosan po!ysuifate, or sail or derivative thereof. </p><p id="p0145" num="0145"> [00116] By way of example, one possible synthetic pathway to provide a conjugate compound of the present invention is described in FIGs 1 and 2. FIG 1 is a reaction scheme for the functionaiisation of HA to present a linker unit while FIG 2 shows reaction schemes representing the synthesis of HA-PPS ( .e. an unmodified PPS bound to HA) and HA-PPSCOOH using the functionatised HA. These reactions are discussed in detail in the experimental section but, in general terms, the HA functionaiisation step involves the coupling of the diamine linker unit to the free oarboxyl of the giucuronic acid sugar of HA, The coupling is performed using standard EDC/NHS coupling chemistry. The modified HA is then coupled to PPS and PPSOGOH to provide the- conjugate compound products. The scheme of FIG 2 shows that the coupling occurs at the carboxyi group of the 4~metbyigiucopyranosyluronic acid of the PPS or PPSCOOH- Thus, a HA will be coupled to every tenth xylopyranose repeat unit of PPS. This coupling step is also performed using standard EDC/NHS coupling chemistry. The characterisation of the functiona!ised HA and the HA-PPS and HA-PPSCOOH conjugates is presented in the experimental section and accompanying figures. </p><p id="p0146" num="0146"> [001 7] It should be noted that prior to the diamine functionaiisation of HA it may be reacted with a compound which can assist with the later cross linking step to form a hydrogei, if such an approach is desired. In one embodiment, the HA will be reacted with a compound which presents both an amine group, for reaction at a portion of the HA free carboxyi groups, and a hydroxy! group for later reaction with a functional group presented by PEG to allow cross linking 
<!-- EPO <DP n="27"/>-->
 and scs hydrogei formation. One preferred example of such a compound is a tyramine salt. Thus the HA will initially be funeiionalised, to an extent, with tyramine to present a phenolic hydroxy! group before subsequently undergoing reaction with the diamine linker, as described, to thereby present a functionaiised HA species ready to be coupled with PPS or PPSCOOH and to subsequently undergo a radical coupling reaction with functsonalised PEG. in the experimental section the tyramine funeiionalised HA is referred to as HA-IYR and when this compound is subsequently further functsonalised with the diamine linker it may be referred to as HA-TYR- HS. </p><p id="p0147" num="0147"> [00118] A third aspect of the invention resides in a conjugate compound produced by the method of the second aspect. The conjugate compound is a hyaluronic acid/PPS conjugate as described for the first aspect of the invention. </p><p id="p0148" num="0148"> [00119] According to a fourth aspect of the invention there is provided a pharmaceutical composition comprising an effective amount of a conjugate compound of the first or third aspect, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent and/or excipient. </p><p id="p0149" num="0149"> [00120] A fifth aspect of the invention resides in a method of treating or preventing a disease, disorder or condition responsive to connective tissue repair and/or maintenance in a patient including the step of administering an effective amount of a conjugate compound of the first or third aspect and piuripotent or multipotent stem ceils, and/or progeny ceiis thereof, or the pharmaceutical composition of file fourth aspect to the affected or potentially affected tissue. </p><p id="p0150" num="0150"> [00 21 ] A sixth aspect of the invention provides for a conjugate compound of the first or third aspect, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophy!axis of a disease, disorder or condition responsive to connective tissue repair and/or maintenance in a patient. </p><p id="p0151" num="0151"> [00122] A seventh aspect of the invention resides in a method of enhancing, promoting or maintaining the chondrogenic potential of a stem csli including the step of contacting the stem cell with the conjugate compound of the first or third aspect. 
<!-- EPO <DP n="28"/>-->
 [00123] An eighth aspect of the invention resides in a method of reducing or inhibiting the osteogenic differentiation of a stem ceii including the step of contacting the stem eel! with the conjugate compound of the first or third aspect. The stern ceil may be selected from the group consisting of MPCs, DPSCs and PDLSCs, </p><p id="p0152" num="0152"> [00124] A ninth aspect of the invention resides in the use of the conjugate compound of the first or third aspects in the manufacture of a medicament for the treatment or prophylaxis of a disease, disorder or condition responsive to connective tissue repair and/or maintenance. </p><p id="p0153" num="0153">[00125] Suitably, the pharmaceutical composition is for the treatment or prophylaxis of a disease, disorder or condition responsive to connective tissue repair and/or maintenance, such as connective tissue degeneration. </p><p id="p0154" num="0154">|00128] !n one embodiment, the pharmaceutical composition further comprises multipotent stem cei!s. in one particular embodiment, the pharmaceutical composition may take the form of a polymeric matrix within which the conjugate compound of the first or third aspect and a multipotent stem ceii population are located. Preferably, the polymeric matrix is a hydroge!. Suitably, the hydrogei is comprised of cross linked polyethylene glycol and hyaluronic acid units. This pharmaceutical composition is suitable for use with the methods of the invention. The chondrogenic or osteogenic differentiation of the multipotent stem oei!s may be promoted. </p><p id="p0155" num="0155">[00127] The hydrogei may be formed by cross finking of tyramine functionaiised HA and PEG functionaiised with a hydroxyaeid such as 3-(4-hydroxyphenyl}propionic acid (HPA). Further functionalities suitable for achieving cross linking to effect hydrogei formation may be suitable and would be well Known in the art of polymer chemistry. The conjugate compounds of the invention may, in one embodiment, be present during the cross linking initiation step such that they become incorporated, i.e. bound, into the hydrogei scaffold. This is a particularly preferred embodiment for treatment of IVD degeneration 
<!-- EPO <DP n="29"/>-->
 due to the physics! structure of the functionalised hydrogel which may be injected into the site of damage. </p><p id="p0156" num="0156">[00128] The MPCs can also he present at hydrogel formation to thereby have them effectively encapsulated into the hydrogel matrix and in contact with bound conjugate compounds of the invention. </p><p id="p0157" num="0157"> [00129] The pharmaceutical composition may comprise further additives selected from the group consisting of glycosaminoglycan (GAG), unbound hyaluronic acid (HA), chondroitin sulphate, dermatan sulphate, keratin sulphate, heparin, heparin sulphate and unbound PPS. These additives may bring additional benefit to PC differentiation or may contribute more directly to repair of connective tissue. </p><p id="p0158" num="0158"> 100130] The pharmaceutical composition may include more than one conjugate compound of the first or third aspect. When the composition includes more than one conjugate compound then the conjugate compounds may be in any ratio. Preferably, the conjugate compound of the first or third aspect in the pharmaceutical composition is HA-PPS and/or HA-PPScoot. </p><p id="p0159" num="0159"> [00131 The conjugate compounds of the first or third aspect are present in the pharmaceutical composition in an amount sufficient to prevent, inhibit or ameliorate the disease, disorder or condition which is the subject of treatment. Suitable dosage forms and rates of the compounds of the first or third aspect and the pharmaceutical compositions containing such may be readily determined by those skilled in the art, </p><p id="p0160" num="0160"> [00132] Dosage forms may include tablets, dispersions, suspensions, injections, solutions, syrups, troches, capsules and the like. These dosage forms may also include injecting or implanting devices designed specifically for, or modified to, ensure placement at the site of connective tissue degradation. A hydrogel is a preferred delivery form. </p><p id="p0161" num="0161"> [00133] The disease, disorder or condition to be treated will be caused by or in some way related to connective tissue degradation and will be responsive to connective tissue repair and/or maintenance and/or reoonsiitution. 
<!-- EPO <DP n="30"/>-->
 [00134] Preferably, the affected tissue is a cartilaginous structure, such as an intervertebral disc, articular cartilage or a meniscus; bone; tendon; ligament; and components of teeth. </p><p id="p0162" num="0162"> [00135] The conjugate compound of the first or third aspects and multipoint stem ceils, and/or progeny cells thereof, may be co-administered. Preferably, the conjugate compound and multipotent stem cells, and/or progeny cells thereof, are co-administered within a polymeric matrix, such as a hydrogel. </p><p id="p0163" num="0163"> [00138) The muitipotent stem ceiis suitable for use with the pharmaceutical compositions and methods of the present invention may be selected from the group consisting of roesechymai precursor ceils {IVtPCs}, dentai pulp stem cells {DPSCs} and periodontal ligament stem ceiis (PDLSCs). The multipotent stem ceils may be derived from induced piutipoteni stem cells (iPSCs) </p><p id="p0164" num="0164"> [00137] Preferably, the multipotent ste n cells are MPCs. According to this embodiment, the conjugate compound of the first or third aspects and the MFCs are administered to connective tissue in need of treatment mder conditions which allow proliferation of the MPCs and differentiation of the MPCs into chondrocytes to thereby repair or regenerate the connective tissue. One particular example is the repair of a damaged intervertebral disc. </p><p id="p0165" num="0165"> [00138] As used herein, "subject" or "individual" or "<sup>'</sup>patient" refers to any subject, for whom or which therapy is desired, and generally refers to the recipient of the therapy to be practiced according to the invention. The subject can be any vertebrate, but will preferably be a mammal, if a mammal, the subject will preferably be a human, but may also be a domestic livestock, laboratory subject or pet animal. The subject is most preferably a human adult, child or infant, who is or has been the object of treatment, observation or experiment. </p><p id="p0166" num="0166"> [00 39] Contacting multipotent stem cells with the conjugate compounds of the invention may, in one embodiment, inhibit or reduce the extent of osteogenic differentiation. It has been surprisingly found that the conjugate compounds of the invention are strongly inhibiting of osteogenic differentiation even In the presence of promoting molecules such as B P-6. This can be 
<!-- EPO <DP n="31"/>-->
 useful in inhibiting the differentiation of a population of stem cells at the chondrogenic stage when they wouid otherwise proceed to osteogenesis. This provides an additional advantage or layer of control in treating the conditions described herein. </p><p id="p0167" num="0167"> [00140] Although not wishing to be bound by theory, the conjugate compound of the first or third aspects induces elevated expression of chondrogenic markers including GAG, Sox9 and Coilagen-!l by the MFCs, which correlate with improved or enhanced chondrogenic potential. The use of these conjugate compounds in a composition, such as a hydrogel, which also contains MFCs can result In chondrogenic differentiation thereof to form a supportive cartilaginous matrix useful in the repair of degenerated cartilage- containing tissues, in the presence of osteogenic promoting factors the conjugate compound of the first or third aspects may induce elevated expression oi osteogenic markers including Runx2 and Coi1 1 . </p><p id="p0168" num="0168"> [00141 ] The following experimental section describes in more detail the formation of the conjugate compounds of the invention, their characterisation, their incorporation into a hydrogel and their eff ect on PC differentiation, The intention is to illustrate the production of specific embodiments of the conjugate compound and their efficacy without limiting the invention in any way. </p><p id="p0169" num="0169">EXPERIMENTAL </p><p id="p0170" num="0170"> Materials </p><p id="p0171" num="0171"> [00142] Hya!uronic acid of 215kDa molecular weight was purchased from Llfecore. Amine terminated 8 - arm poiy(ethylenegiycol) (P£G, tripentaerythritoi backbone, ?i w ·<sup>»</sup> 40 kDa) was purchased from JenKem, USA. 3-(4- hydroxyphenyOpropionic acid (HPA), N-(3-dimethylaminopropyi)~N'- ethyicarbodlimide hydrochloride (EDC), -hydroxysuccinimide (NHS), peroxidase, Type i from horseradish (HRP, 113 U/mg solid) were all purchased from Sigma, Sodium PPS (Batch Q18) was supplied by hene-Arzneimittel 
<!-- EPO <DP n="32"/>-->
 GmbH (Munich, Germany). AIS other reagents were purchased from Gibco unless otherwise stated. </p><p id="p0172" num="0172"> Reactions </p><p id="p0173" num="0173"> F nctiorsa!isaiion of HA with tyrarome to facilitate crossfmkmg </p><p id="p0174" num="0174">[00143] HA was reacted with lyramine hydrochloride and 1 -Ethyi-3- [3-dimethyiaminopropyljearbodiirnjde hydrochloride / N-hydroxysuccinimide (EDC/NHS) in a 1 :10:0.1 molar ratio in 0.1 MES buffer, pH 4.8. Solutions of HA and tyramine were mixed to produce the desired concentration, the pH readjusted to 4.8 and EDC/NHS added. After 15 min, sodium hydroxide was used to adjust the pH to 5.8 and the reaction left to proceed for 3hrs at room temperature with gentle agitation. Unreacted products were removed by dialysis in 3500 MWCO tubing (ThermoFisher) for 48hrs each against 150 mM NaCi, 10% ethanoi and distilled water and the purified samples frseze-dried. The product of this reaction is referred to as HA- *. </p><p id="p0175" num="0175"> Functionalisaiiors of PEG with HPA to facilitate crosslirtkmg </p><p id="p0176" num="0176"> [001 4] PEG was reacted with 3-4- ydroxyphenySpropionic acid (HPA) using EDC/NHS chemistry. Briefly, HPA was dissolved in 0.1 M MES buffer to a concentration of 5m and the pH adjusted to 4.8. A solution of 500μΜ EDC and 50μΜ NHS was added and reacted for 5 min at room temperature. A solution of PEG in 0.1 M MES buffer was added to give a final concentration of 82.5pM and the pH adjusted to 5.8. The reaction was left to proceed for3 hrs at room temperature with gentle agitation and repeated up to four times to achieve the desired degree oi funciionaiisation. Dialysis was performed for 24hrs after each reaction in 150 rnM NaCi solution using 3500 MWCO tubing. After the final reaction, a more extensive dialysis process of 24 hours in 150 A NaCi, 24 hours in 20 % ethanoi and a further 24 hours in distilled water was performed and the samples freeze-dried. </p><p id="p0177" num="0177"> F ncisonatisaiion of HA-rm with amine groups for PPS coupling </p><p id="p0178" num="0178"> [00145] BArs-R was further functional sed to present amine groups using cystamsne hydrochloride and EDC/NHS In a 1 :10:10 molar ratio of acid groups 
<!-- EPO <DP n="33"/>-->
 on HArvR ystamine hydrochioride:EDC. The reagents were dissolved in 0.1 MES buffer, pH 4.8 and reacted for 3 hrs at room temperature with gentle agitation. Samples were dialysed in 3S00-MWCO tubing for 48hrs each against 150 rri NaCi, 10% ethane! and disiiiied water prior .to freeze- y sng. The product of this reaction is be referred to as HA<sub>T</sub>VR- H2 in the figures and the success of this reaction can be seen in FiG 4 w ich is discussed further below.</p><p id="p0179" num="0179">Carboxylatson of PPS </p><p id="p0180" num="0180"> [00146] PPS was dissolved in 1 SV1 ch!oroacefic acid, an equal vo!ume of 3 sodium hydroxide added and reacted at room temperature for <sup>"</sup>/Groin with gentle agitation. The reactio was stopped by the addition of 4mg/ml sodium dihydrogen phosphate and neutralised with 8N hydrochloric acid. Un-reacted products were removed by dialysis against water in 10kDa dialysis tubing, with regular changes over a 48hr period. The solution was freeze-dried to obtain car oxylated PPS (PPSCOOH)-</p><p id="p0181" num="0181">[00147] The formation of additional carbonyi groups on the PPS following this reation can be viewed using FTIR as seen in FiG 3. FTiR indicates the gain of a peak at 720, corresponding to the C~Q stretch from the new acid groups thereby indicating successful functionalisation. </p><p id="p0182" num="0182"> Coupling of HA with PPS or PPSCOOH </p><p id="p0183" num="0183"> [00 48} A solution of HATYR-NHJ and either PPS or PPSCOOH and EDC/NHS in a 1 :5:5 molar ratio was made up in 0.1 M MES buffer, pH 4.8 and reacted at room temperature, with gentle agitation for 2hrs. Samples were dialysed in 10,000 VVCO tubing for 48hrs each against 150 mM NaCi, 10% eihanoi and distilled water priorto freeze-drying. The produd of this reaction is referred to in FiG 4 as either HArm-NHjPPS Of HATYR- NH.PPSCOOH </p><p id="p0184" num="0184"> (00 9] The success of the reaction to functionalise HATY .with amine groups forming HATY - HZ was confirmed by FTIR as is shown in FiG 4A, which is an ATR-FTIR overlay of HArv;¾ and HATYR-NH<sub>2</sub>, b the gain of a peak at 1700- 750, corresponding to the formation of an amide bond, A TNBSA assay, as seen in FiG 4B, for amine groups also showed an increase after amine 
<!-- EPO <DP n="34"/>-->
 funetlonalisation of HATYR. Quantitation showed a degree of functionaiisation of 8% of available acid groups in the HA molecule, providing a large number of groups available to be bound by PPS. Subsequent testing of HATYR-MH<sub>;:</sub> after coupling with PPS or PPSCOOK showed a decrease in the number of amine groups, suggesting that these had been removed by the coupling to PPS. MR analysis of HA-PFS and HA-PPSCCOH confirmed the direct coupling of PPS to HA and showed a degree of substitution of 3% for HA-FPS, with 75% of the PPS being directly bound. The degree of substitution was 8% for the HA-PPScoo<sub>H</sub> an gradient NMR showed that 68% of this was covaientiy bound to the HA, </p><p id="p0185" num="0185"> Characterisation of Materials </p><p id="p0186" num="0186">TNBSA assay </p><p id="p0187" num="0187"> [00150] The degree of amine substitution of HA was measured by 4,6-trtnitrobenzene sulfonic acid (TNBSA) assay {Thermo Scientific, USA). Briefly, 10Qpi of 20{fyg/m! sample in carbonate buffer (2:1 , vol: vol of 0.2M a<sub>2</sub>C0<sub>3</sub> to 0.2M NaHC0<sub>3(</sub> pH 10.2) was plated out and 5Gpi 0.01% TNBSA added. Samples were run in triplicate and the degree of substitution determined by comparison to a standard curve produced using glycine. </p><p id="p0188" num="0188"> FTI </p><p id="p0189" num="0189"> [00 51] Samples were analysed by Fourier transform infra red (AT -FTIR) using a Thermo Scientific Nicolst 5700 spectrophotometer, equipped with an attenuated total reflectance (ATR) module (Smart Omni sampler, GE crystal). Spectra were collected in the mid-I range (500-4000 cm at a resolution of 6.0 cm ' and signal averaged over 128 scans. </p><p id="p0190" num="0190"> HMR</p><p id="p0191" num="0191">00152] Quantitative 1 H NMR (750 MHz) spectra were acquired oh a Bruker Avance 750 high-resolution NMR spectrometer. The chemical shifts were referenced to the solvent resonance (DjO) at δ = 4.77 ppm. The degree of substitution of HPA on the PEG molecules (ds) was calculated from the relative integral of the methylene resonance from PEG (5 - 3.7 ppm) compared to that of the aromatic resonances attributed to the HPA (6 ~ 6.8 and 7.1 ppm). 
<!-- EPO <DP n="35"/>-->
 normalizing to the number of contributing protons. To ensure the peaks observed for HPA were arising from HPA eovalently bound to PEG., pulsed diffusion gradient 1 H N R was employed and the variation of the aromatic- peak intensities compared to the quantitative scans against the normalised methylene peak of the PEG. </p><p id="p0192" num="0192"> [00153] Similarly, the degree of substitution of TY on the ΗΑ<sub>Τ</sub>γ<sub>$</sub>¾ was calculated by comparing the relative peak integrals of the aromatic protons of TYR (δ - 6.8 and 7.1 ppm) and the HA methyl protons (5 = 1.9 ppm). For the HA-PPS conjugates, a comparison of the relative integrals was made between the anomeric proton of the PPS (5 = 5.2 ppm) and the methyl proton of HA δ - 1.9 ppm) to determine the degree of PPS substitution. Pulsed gradient diffusion HMR Vv'as aiso performed on these samples to observe and approximate the amount of bound maoromer, against the normalised HA methyl peak. </p><p id="p0193" num="0193"> Effect of HA- PPS and HA -PPS OQH on MPCs in solution </p><p id="p0194" num="0194"> !yiPC culture </p><p id="p0195" num="0195"> [00154] Stro - selected human MPCs were prepared by Lonza (Wafkersville, USA) for Mesoblast Ltd {Melbourne, Australia) according to the isolation procedure described by Gronthos et al [7], MPCs were cultured in alphafvE supplemented with 100 U/m! penicillin, 100 pg rnl streptomycin (Gibco fnvitrogen Carlsbad, CA. USA), 10% batchtested foetal bovine serum (FBS), 2m L-Giutamine, I mM Sodium Pyruvate, and Ι ΟΟμ L-ascorbate-2-Phosphate. Tissue culture flasks were maintained at 3?°C in 5% CC¾ in an atmosphere with 95% humidity. Upon reaching 70% confluence MPCs were passaged, rep!atihg at 2000 celis cm2, </p><p id="p0196" num="0196"> Proliferation of MPCs treated with HA - PPS and HA - PPSCOOH </p><p id="p0197" num="0197">[00155] MPCs were seeded at a density of 2000 cefis cm2 in a 96-weli plate and allowed to adhere for 4 hrs at which point the medium was exchanged for iVlPC maintenance medium supplemented with PPS, HA, HA-PPS and HA-PPSoooH at concentrations equivalent to 5, 1 and 20pg/ml unbound PPS. MPCs were cultured for 7 days with media changes every 2-3 days and the cell 
<!-- EPO <DP n="36"/>-->
 number determined by CCK8 assay (Sigma). Briefly, the culture medium was replaced with 10Ομί UPC maintenance medium (without, phenol red) containing 10% (v/v) CCK8. After 2 hrs the absorbance was read at 450nm. Ail samples were performed in triplicate and normalised to blank medium without ceiis. </p><p id="p0198" num="0198"> [00158] The effects of HA-PPS on MPC proliferation are shown in the CCK8 assay of FIG 8 (data Is shown as mean ±SEM pO.05 {*), p 0.01 {**}, p&lt;0.001 (***) with the results for two independent MPC donors pooled together). Treatment with both HA-PPS and HA-PPSCOOH resulted in a dose-dependent decrease in MPC proliferation. Treatment with HA alone did not have this effect, !t is likely that this corresponds with observed changes in cell morphology and induction of (chondrogenic) differentiation. </p><p id="p0199" num="0199"> Chondrogenic differentiation of MPC&amp; treated with HA - PPS and HA · PPSCOOH </p><p id="p0200" num="0200"> [00157] Chondrogenic differentiation was compared for MPCs cultured in maintenance medium and treated with PPS, HA, HA-PPS and HA-PPSCOOH a* concentrations equivalent to 5, 10 and 20pg/ml unbound PPS. These factors were added to the cells prior to peliel formation, which was initiated by cent ifuging 2x105 MPCs in a non-adherent U-bottom plate at 500g for 10min. MPC peliets were cultured In 200μΙ medium with media changes every 3-4 days. After 21 days, samples were taken for analysis by histological staining, D MB assay and qPCR. </p><p id="p0201" num="0201"> [00158] The gene expression of MPCs treated with HA-PPS and HA-PPSCOOH was analysed with the results displayed in FIG 7 (data is shown as mean ±SEM, p&lt;0.05 (*), p&lt;0.01 .(**}, p&lt;0.001 {***) with the results for two independent MPC donors pooled together). In the absence of any differentiation factors, both PPS and HA-PPS caused a small but significant decrease of the osteogenic transcription factor Runx2. Expression of 8MP13 {which has been linked to chondrogenic differentiation) was significantly Increased by PPS, HA-PPS and HA-PPSCOOH over untreated controls. HA alone had no effect. Expression of the BMP antagonist, Noggin, was decreased by PPS treatment 
<!-- EPO <DP n="37"/>-->
 and to a lesser extent HA-PPS and HA-PPSCOOH- These results therefore indicate that the presence of HA-PPS and/or HA-PPSCOOH promotes chondrogenic differentiation of MFCs. </p><p id="p0202" num="0202"> Osteogenic differentiation of MPCs treated with HA - PPS </p><p id="p0203" num="0203">[00159] MFCs were plated at a density of 20,000 ceils/cm2 and left to adhere for 24hrs before changing the medium to osteogenic medium {D EM-LG, 100 U/mi penicillin, 100 pg ml streptomycin, 10% FBS, 100 ng mL dexamethasone, 50 uM ascorbate-2-phosphate and 10 mM β- glycerophosphate) supplemented with BMP-6 (100 ng/ml) and HA-PPS at concentrations equivalent to 5, 10 and 20pg/mi unbound PPS. Repeat expenments were also performed in the absence of FBS. The cultures were maintained for 21 days with media changes every 3-4 days. The extent of osteogenic differentiation was determined by Alizarin red staining, alkaline phosphatase staining and alkaline phosphatase activity relative to DNA content (pNPP assay). </p><p id="p0204" num="0204"> [001601 FiGs 8A to 8C indicate the resuits of this experiment. FIG 8A is a series of images showing Alizarin red staining in FBS{+} and FSS(-) media of untreated and osteogenic controls, and at 16. 32 and 64 g mL HA-PPS, with and without 100 ng/mL BMP-6 at day 2 Scale bar ~ 200 pro. The images show that there was an apparent increase in mineralization seen in the FBS{+) osteogenic and B P-6 controls relative to the FBS{-) ones. Compared to the osteogenic control, the addition of HA-PPS at all concentrations (with or without FBS) substantially inhibits mineralisation, with similar levels as observed in the untreated control. They also show substantial reductions in mineralization having occurred in all 8MP-6 conditions for the FBS(^) conditions at all concentrations of HA-PPS; these findings were not seen in the FBS{-) counterparts. Importantly, the addition of HA-PPS. at all concentrations, is seen to effectively inhibit mineralization and hence osteogenic differentiation. This is seen even when the HA-PPS was delivered along with BMP-6 with relatively low levels of mineralization observed. </p><p id="p0205" num="0205"> [00161] FIG 8B is &amp; series of images showing alkaline phosphatase (ALP) staining .in FBS(+) and FBS(-) media of untreated, osteogenic and BMP-6 
<!-- EPO <DP n="38"/>-->
 controls, and ai 16, 32 and 64 pg/mL HA-PPS, both in the presence and absence of 100 ng/mL BMP-6 at day 7. Scale bar = 200 pro. FIG 8C shows a graphical output of the alkaline phosphatase activity relative to DMA content (p PP assay). Reference to both of these figures demonstrates that FBS{+) media supported greater hivISC ALP activity than FBS{-} media for all conditions at day-7. Ail concentrations of HA-PPS in the absence of BMP-6 resuited in substantial reduction in ALP activity compared to the osteogenic control Ail HA-PPS conditions with B P-6 resulted in substantial reductions in ALP activity compared to the BMP-6 control. ALP activity did not appearto vary with change in HA-PPS concentration. Osteogenic media stained more greatiy for ALP than undifferentiated media in both the presence and absence of FBS.</p><p id="p0206" num="0206">Alizarin red staining arsd quantification </p><p id="p0207" num="0207"> [00162] Day 21 osteogenic cultures were rinsed with PBS, fixed in 4% paraformaldehyde for 20 min and stained with 2% Alizarin red, pH4.2 for 30 minutes. Excess dye was removed by thorough washing with dH20 and images obtained. For quantification, dye was extracted with 10% cetylpyridinium chloride in 10m sodium phosphate and the absorbance read at 540nm. Samples were performed in triplicate and normalised to undifferentiated controls. </p><p id="p0208" num="0208"> Alkaline hosphasate (pNPP) assay </p><p id="p0209" num="0209"> |00163] Day 7 osteogenic cultures were iysed in 150 pi 0 1 % Triton-X-100 in 0.2 carbonate buffer and subjected to 3 freeze-thaw cycles between -80<sup>::</sup>C and 37<sup>*</sup>C. To determine alkaiine phosphatase activity, 50 pi working substrate {0,3 mg/mi pNPP (Sigma) and 3.3 m Mg&lt;¾ in 0.2 carbonate buffer) was added to each sample and incubsted at 37<sup>*</sup>C before measurement of the absorbance on a Spectramax fv15 Fiuorometsr (Molecular Devices) with an excitation wavelength of 405 nm, pNPP concentration was determined by extrapolation from a standard curve and normalized to both incubation time and DNA content as assessed by PicoGresn assay (Molecular Probes, performed according to the manufacturer's instructions). </p><p id="p0210" num="0210"> OM B assay 
<!-- EPO <DP n="39"/>-->
 [00164] Chondrogenic pellets were collected, rinsed in PBS and !ysed in I mg/mi Papain in 100mM sodium phosphate, 5 mM EDTA and 5mM L-cystein (pH 6.5) overnight at 60°C. Samples of 40μΙ were plated In triplicate with the addition of 10 pi 1%BSA in PBS and 5ppl 2x 1,9-dimethylmeihylene blue (DMMB). These were incubated at room temperature for 15 mm and the ahsorbance at 525 nm read using a Spectramax M5 Fiuorometer {Molecular Devices). Samples were normalised to DNA content as assessed by PieoGreen assay (Molecular Probes: performed according to the manufacturer's instructions). </p><p id="p0211" num="0211"> {00165} St is important to note that this protocol was carried out in the absence of any additional factors commonly used to initiate ehondrogenesis (e.g. TGFjJ). After 21 days, a O MB assay for GAG content showed that pellets treated with PPS, HA-PPS and HA-PPSGOOH ail had significantly greater GAG content than untreated pellets or pellets treated with HA alone. These results are presented in FIG 9A and 9B. PPS alone increased GAG deposition to 150% of thai of untreated pellets, an effect that was enhanced further with HA-PPS and HA-PPScoo<sub>H</sub> which had a GAG content of 200 and 250% of untreated pellets respectively, significantly higher than lor PPS alone, Alcian blue and Safranin O staining (for sGAGs) also showed increased intensity for pellets treated with HA-PPS and HA-PPSCOOH compared to unbound PPS, suggestive of a greater deposition of GAGs and proteoglycans characteristic of chondrogenic differentiation. </p><p id="p0212" num="0212"> [00166] This is a very significant finding which demonstrates that the conjugate compounds of the invention are capable, importantly even in ins absence of assisting chondrogenic factors, of strongly promoting production of Important matrix materials such as GAG by MFCs due to the chondrogenic differentiation the influence. Details of the PGR analysis, sectioning and staining procedures are presented below, </p><p id="p0213" num="0213"> Cryoseetlortsng and histological staining of chondrogenic pellets</p><p id="p0214" num="0214">(00167] Samples were fixed in 4% paraformaldehyde for 20 min, rinsed with</p><p id="p0215" num="0215">PBS and incubated in a 1 :1 mixture of OCT: 30% sucrose for 4hrs followed by 
<!-- EPO <DP n="40"/>-->
 OCT overnight. Samples were then snap frozen and 8μ sections taken sectioned using a Leica 3050n cr ostat. Sections were stained with Alcian blue, Toiuidine blue and Safranin O using standard histological procedures.</p><p id="p0216" num="0216"> PC analy is of MPC cultures </p><p id="p0217" num="0217"> [00168] Total RHA was extracted using an RNeasy Minikit with on-column DNase treatment (Qiagen) according to the manufacturer's instructions, cDNA was synthesized from 250ng RNA, or the equivalent volume of DNase and RNasefree water for no-RT controls, using the Superscript® Hi First-Strand Synthesis System (invitrogen). qPCR reactions were set up in &amp; total volume of 10μΙ with f x Platinum SYSR Green qPCR Super ix-UDG (invitrogen) and 0.2μ forward and reverse primers. A 7500 Fast Real-Time PGR System (Applied Biosystems) with fast cycling parameters of 2 min at 5CfC, 2 min at 95<sup>::</sup>C then 40 cycles of 3sec at 95°C and 30sec at 60°C followed by a melt curve was used to run the samples. Data was analysed using the 2-<sup>"</sup>^ method and normalized back to untreated monolayer levels. </p><p id="p0218" num="0218"> HA/PEG hydrogels incorporating soluble and bound PPS </p><p id="p0219" num="0219">Rheoiogieai characterisation of HA/PEG hydrogsfs </p><p id="p0220" num="0220">[00169] Ail rheologicai measurements were obtained using an AR G2 rheometer (TA Instruments, New Castle, DE) in oscillatory mode using a 20 mm diameter stainless steel flat plate and lower Teflon Pel!etier surface. The gels were synthesized and, upon addition of the H<sub>2</sub>0<sub>¾</sub>, immediately vortexed and loaded between the plates of the rheometer with a gap measurement of 10OOum. Gelation kinetics and final moduli were determined by iimesweeps at 37"C, conducted with a controlled strain of 1 % and an angular frequency of 6.28 rad/sec. Frequency sweeps were performed between 5.000E-3 to 50 rad/sec at 1% strain. Stress sweeps confirmed that this was within the linear viscoeiastic region. </p><p id="p0221" num="0221"> [00170] Data from the rheologicai characterisation of the PEG/HA hydrogels incorporating soiubie PPS or HA-PPS is given in table 1. Soluble PPS was incorporated into the gel mixture prior to crosslinking, while HA-PPS was incorporated info gels to provide a covaientiy bound form of PPS. Rheologicai 
<!-- EPO <DP n="41"/>-->
 analysis of the properties of the resulting hydrogels showed that incorporation of both soluble and bound PPS (HA-PPS) causes a small decrease in resulting modulus and slows the gelation process, although the resulting hydrogels still maintained properties well within the limits required for transfer to clinical use.</p><p id="p0222" num="0222">Swelling and degradation </p><p id="p0223" num="0223"> [00171] To determine the degree of swelling, 50μΙ gels were synthesized and the dry weight obtained after fresze-drying for 24 hrs ( <sub>a</sub>). The gels were then incubated in 500μΙ PBS for 24hrs at 37<sup>S</sup>C. The PBS was removed and the gels reweighed (W<sub>s</sub>). The degree of swelling was determined by {(W<sub>s</sub>- W«) /W<sub>d</sub>) using triplicate gels for each condition. Degradation of 50pi gels was measured over a period of 3 months using triplicate samples for each condition. After synthesis, the gels were incubated In PBS/0.01% Sodium azide at 37"C with weekly changes of buffer. At specific timepoirsts aii excess PBS was removed and the gels weighed. The degree of degradation was expressed as a % of the original gel mass.</p><p id="p0224" num="0224">00172] Data is presented in FIG 0A (swelling profile) and 10B (degradation profile) wherein all data is shown as mean ±SE , N=3. p&lt;0.05 (*). Analysis of the swelling and degradation properiles of the hydrogels showed a high degree of swelling for ail hydrogels (21 -27%). This was decreased (p&lt;0.05) when PPS or HA-PPS were incorporated into the hydrogeis. The degradation profile for all hydrogels were similar showing that, in the absence of cells, there was minimal degradation over a 3 month period. </p><p id="p0225" num="0225"> [00173] The Etiological, swelling and degradation data indicate that the hydrogei containing conjugate compounds of the invention have appropriate physical properties to provide an IVO scaffold which, in combination with encapsulated MFCs, results in a useful tissue engineered matrix for the treatment of iVD degeneration. </p><p id="p0226" num="0226"> ¾SFC encapsulation and culture in HA/PEG l ydrogels </p><p id="p0227" num="0227">[00174) pcs (P4-6) were encapsulated in geis containing 15mg/mi HATYR, 18,5mg/ml PEGHPA, 0.25U/m! horseradish peroxidase (HRP) and varying amounts of hydrogen peroxide ίΉ<sub>2</sub>ί¾}. Solubie PPS was added into the gels 
<!-- EPO <DP n="42"/>-->
 prior to crossiinking at a final .concentration of Spg/ml. HA-PPS and HA-PPScooH were incorporated at concentrations of 18Mg mi and Spg/mi respectively giving a concentration of PPS equivalent to 5pg/ml unbound PPS. </p><p id="p0228" num="0228"> [00175] MPCs were resuspended to a concentration of 5x10° cells/mi in solution containing all of the components except ¾&lt;¼ and thoroughly mixed. Crossiinking was then initiated by the addition of ¾&lt;¾ and the gels spotted out into lowhlnding tissue culture plates. After 15 minutes, growth media was added to the ef! and the cell/gel composites cultured for up to 21 days with media changes every 3-4 days. </p><p id="p0229" num="0229"> [001 8] When encapsulated in HA/PEG hydroge!s containing PPS and HA- PPS, MPCs retained good viability both after the initial cross-linking pa" cess and for longer term culture periods as shown in FiG 11 which is a live/dead staining of encapsulated !v PCs. Viability of MPCs after 24 hrs and 7 days of encapsulation Is shown with live cei!s in green and dead cells in red (white stars). Scale bar = 50pm. The Images indicate the vast majority of cells remain live </p><p id="p0230" num="0230"> [00177] Histological staining was also used to analyse the structure and matrix content of MPG/hydroge! composites after 21 days culture and the results are shown in FIG 12. H*E staining shows gels embedded within lacunae with a structure analogous to that of native cartilage tissue. Alcian blue staining was enhanced in gels incorporating HA-PPS, with strong staining particularly evident directly around the encapsulated MPCs. This suggests Increased GAG accumulation surrounding MPCs in geis incorporating HA-PPS, as compared to blank geis or those incorporating soluble PPS. Once again, the chondrogenic differentiation of the !v PCs when exposed to a conjugate compound of the invention is shown and this time when within the hydrogei matrix. </p><p id="p0231" num="0231">immunofluorescence </p><p id="p0232" num="0232"> [00178] Samples were fixed in 4% paraformaldehyde for 20 min and rinsed with PBS. To detect Goifagen-tf, the samples were digested with 0,01 % pepsin (w/v). in 0.01 M HCL (pH2) tor 30 min at 3?'C and incubated in 0.1% Triton-X- 00 for 5 min at RT°C before blocking in 2%BSA 2% goat serum for 1 
<!-- EPO <DP n="43"/>-->
 nr. A Collagen-Si antibod (Abcarn ab3Q92) was used at a dilution of 1/50 for 2 hrs followed by incubation with an AlexFluor 488-canjiigated secondary antibody for 1 nr. All samples were eounterstained with Hoechst 33342, mounted in Vectorshieid {Vector laboratories) and imaged by taking z-stacks through the gel with LSR710 confocal microscope (Zeiss). </p><p id="p0233" num="0233"> [00 79] The staining procedure showed deposition of collagen-ll around the encapsulated MFCs which was increased in the presence of PP5 and HA-PPS compared to gels alone, as seen in FIG 3. it was also enhanced in soft gels (crosstinked with 4mH H<sub>2</sub>0<sub>2</sub>) compared to stiff {2.5m ) gels. </p><p id="p0234" num="0234">qPC of MFCs encaps ated in HA/PEG hydrogeis </p><p id="p0235" num="0235">[00180] Total RNA was extracted with QlAzo!, DNase treated in suspension for 40min at room temperature and subsequentl mpurified by QIAzoi extraction. cDNA was synthesized from 50ng RNA, or the equivalent volume of DNase and RNase-free water for πο-RT controls, ussng the Superscript® ill First-Strand Synthesis System (Invitrogen). qPCR reactions were sei-up in a total volume of lOul with 1x Platinum SYBR Green qPCR SuperMix-UDG (Invttrogen) and 0.2μΜ forward and reverse primers. A 7500 Fast Real-Time PGR System (Applied Biosystems) with fast cycling parameters of 2 min at 50<sup>!!</sup>C, 2 min at 95°C then 40 cycles of 3sec at 95<sup>«</sup>C and 30seo at 60 "C followed by a roeit curve was used to run the samples. Data was analysed using the
<img id="imgf000043_0001" he="5" wi="27" file="imgf000043_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 normalized back to untreated monolayer levels. </p><p id="p0236" num="0236"> [00181 ] qPCR analysis of PCs encapsulated for 21 days showed increased expression of the chondrogenic transcription factor, Sox9, in gels incorporating HA-PPS as seen in FIG 14 (data Is shown as mean ±SEM, N 5). Once again the hydrogel incorporating a conjugate compound of the Invention and MPCs is shown to have potential as a treatment for conditions responsive to connectix'e tissue repair or reconstitution and, particularly, for those conditions where placement of a physical scaffold is useful such as in treating IV<sup>'</sup>D degeneration.</p><p id="p0237" num="0237">Further Experiments Using Canine Mesenchymal Stem Cells (MSCs) from induced Piuripotent Stem Ceils (diPSCs) 
<!-- EPO <DP n="44"/>-->
 [001821 Chen and colleagues [9] have described a methodolog whereby human induced p!uripoient stem ceils (IPSCs) and embryonic stem ceiis (ESCs) couid be induced to differentiate into MSCs vis inhibition of the TGFjJ aciivln signaling pathway and maintenance in culture conditions that support an epithelial to mesenchymal transition. By exposing the ceils to the TGFp/activin type I receptor inhibitor SB431542 for just 10 days, and then transitioning the ceils into typical MSG culture conditions, Chen and co-workers generated iPSC- and ESC-derived MSCs that resembled primary MSCs in terms of their immunophenotype and in their ability to differentiate into mesodermal derivatives. </p><p id="p0238" num="0238"> [00183] This SB431S42 induction method, initially described for human pluripotent stem cells., was applied herein to canine iPSCs. Using this methodology canine IPSC-derived MSCs were produced that have an immunophenotype similar to tissue-derived canine MSCs, a high proliferative rate which does not diminish with progressive passage and an ability Io give rise to the three mesoderm derivatives of cartilage, bone and adipose tissue, but which do not form teratomas. The behaviour of the canine iPSC-derived MSCs when incorporated into injectable hydrogel scaffolds designed to optimise chondrogenesis within the milieu of a joint was examined. </p><p id="p0239" num="0239"> Generation and aintenance of iPSCs-dsrived ?$SCs</p><p id="p0240" num="0240">00184] Canine iPSCs (diPSCs) were cultured by known means and were induced to undergo an epithelial to mesenchymal transition using the protocol described by Chen Colonies of diPSCs were enzymatiea!!y passaged with TrypLE (Life Technologies) to yield large clumps of ceiis which were then plated onto T25 tissue culture flasks (Cosiar) coated with Matrigel (8D Biosciences). Cells were cultured for 10 days with 10 MM of the TGFp/<sup>'</sup>activin type ! receptor inhibitor SB431542 (Stemgent) in the medium previously used to support the diPSCs (Knockout DMEM (Life Technologies), 20% (v v) Knockout Serum Replacement (KS ) (Life Technologies), 0.1 mM non-essential amino acids (NEAA) (Life Technologies) and 2 mM L-glutamine (Life Technologies)) but without p-mercaptoethanol and leukaemia inhibitory factor. After 10 days, cells 
<!-- EPO <DP n="45"/>-->
 were passaged with TrypLE to yield a single-eei! suspension and plated directly onto 175 tissue culture flasks (Costar), From this point cells were cultured in MSG medium consisting of Knockout, DME (Life Technologies), 10% {v/vj ESC-quaiifled fetal bovine serum (Life Technologies), 0.1 mM EAA and 2 mM L-glutarnine. Ail cultures were maintained at 37*C with 5% C0<sub>2</sub>. Commercially available canine adipose-derived adult MSCs were kindly supplied by Regeneus Pty Ltd, Vials were thawed and plated onto tissue culture flasks and maintained in MSG medium as described for the diPSC-derived MSCs. </p><p id="p0241" num="0241"> [00185] During 10 days of culture with SB431542 it was observed thai the diPSCs became organised nto a monolayer and assumed a cufooidai to stellate appearance, with ceils becoming more stellate rather than cufooidai at the periphery of the colony. Alter passage into MSG medium, and plating onto uneoated plastic, stei!ate-shaped cells were uniformly distributed as sing!e cells, rather than an epithelial-iike sheet, and closely resembled adipose-derived primary adult MSCs. DiPSC-MSCs express the typical MSG surface markers CD73, CD80 and CD105 as do the adult adipose-derived MSCs and the diPSCs. in contrast, expression of the MSG marker STROI has been acquired by the diPSC-MSCs since it Is not expressed by the diPSCs. Flow cytometry confirmed that the majority of the diPSC-MSCs are positive for the cell surface markers CD73, CD90, CD105 and STRO . DiPSC-MSCs, and adult canine MSCs, also express the pluripotency factors OCT4, NANOG and REX1. Expression of cOCT4 and cNANOG were confirmed at the transcriptional level for both the diPSC-MSCs and adult MSCs, with the diPSCs serving as a positive control. </p><p id="p0242" num="0242">in Vitro Osteogenic, Chondrogsrslc and Adipogsnsc Differentiation Assays </p><p id="p0243" num="0243"> [001861 The ability of the diPSC-MSCs to differentiate into mesodermal derivatives was successfully demonstrated using the Stem-Pro Osteogenesis, Chondrogenesis and Adipogenesis Differentiation Kits (Life Technoiogies). according to the manufacturer instructions. To assess for osteogenesis and chondrogenesis, cultures were stained with Alizarin Red S and Alcian Blue (pH 1 ,0), respectively, as per standard protocols Adipogenesis was determined by 
<!-- EPO <DP n="46"/>-->
 staining with HCS LipltiTOX Red (Life Technologies) according to the manufacturer's instructions. Nuclei were visualised with DAPI. </p><p id="p0244" num="0244"> Encapsulation and Culture of diPSC- SCs in Hydrogeis </p><p id="p0245" num="0245"> [00187] Hydrogeis were prepared as described earlier. Hydrogeis of 3 different compositions were used: a) po!y( ethylene glycol) (PEG) (JenKem); b) PEG and hyaluronic acid (HA) (Lifecore) and c) PEG, HA and HA~ pentosan po!ysulphate (PPS) (HA conjugated to pentosan polysulphafe prepared as described hereinbefore). DiPSC-MSCs were encapsulated in the hydrogeis at a density of 1x107 cells/ml. 50 μΙ of celi/hydrogel composite was spotted onto glass coverslips and piaced into 48-well low binding tissue culture plates (Costar). Triplicates of each of the 3 types of hydrogel were cultured in each of 3 types of medium: basal medium (DME supplemented with 100 U mi penicillin. 100 pg/mS streptomycin and 0% fetal bovine serum (FBS) (all Life Technologies)); osteogenic medium (DMEM supplemented with 100 U/mi penicillin, 100 pg/mS streptomycin, 10% FBS, 100 ng/mL dexametbasone (Sigma), 50 μίνΐ ascorbaie~2-phosphafe (Sigma) and 10 mM β~ glycerophosphate (Sigma)) and chondrogenic medium (DMEM high glucose supplemented with 100 U/mi peniciliin, 100 pg mi streptomycin, 10 mg/mL insulin (Life Technologies), 5.5 mg/mL transferrin (Life Technologies), 5 ng/mL sodium se!enite (Life Technologies), 3mM ilnoisic acid (Life Technoiogies), 3mM oleic acid (Life Technologies), 1 mg mL BSA (Life Technologies), 10 ug/ml sodium pyruvate (Life Technologies), 4 g/ml L-pro!ine (Sigma), 1 mM dexametbasone, 50 piv! ascor ate-2-phosphate and 10 tig/ml TGF(¾3 (Peprotech)). Ceil/hydrogei composites were cultured for 21 days, with medium changes every 3 days, before processing for histology. Paraffin sections were stained with haematoxylin and eosin, Alizarin red S and Aician blue (pH 2.0) according to standard protocols. </p><p id="p0246" num="0246"> [00188] After encapsulation in the hydrogel matrix, diPSC-MSC hydrogel composites were spotted onto glass ccsversiips In tissue culture plates. Under these three-dimensional conditions the cells adopted a rounded morphology that was maintained for the 2 -day culture period. The structure of the 
<!-- EPO <DP n="47"/>-->
 48 </p><p id="p0247" num="0247">cell/hydroge! composites was assessed by haematoxyiin and eosin staining after 21 days and showed a relatively even distribuiion of ceils throughout ail of the hydrogei matrices with the rounded cells residing within lacuna-like structures, interestingly, the size of these lacunae was much larger in the gels containing PEG aione than in those containing both PEG and HA. There were no significant differences in cell morphology between any of the h drogei compositions or medium formulations. </p><p id="p0248" num="0248"> £00189] Aldan Blue staining for the deposition of giycosaminoglycans (GAG) was used as a marker of chondrogenic differentiation. Due to the background staining of the hydrogeis (and particularly those containing HA), positive staining was determined to be any area more intense than the overall background matrix. Little GAG deposition was observed by ceils encapsulated in either the PEG or PEG/HA gels, even in the presence of chondrogenic supplements. However, there were many areas of intense Aician blue staining both surrounding, and between, diPSC-MSCs in PEG/HA+HA-PPS gels in the presence of chondrogenic supplements being strongly suggestive of chondrogenic differentiation. Conversely, whilst there was an abundance of Alizarin Red-positive deposits in the PEG hydrogeis cultured in osteogenic medium, differentiation was significantly reduced in the PEG/HA and HA-PPS hydrogeis. </p><p id="p0249" num="0249"> [00190] These results show that canine iPSCs can be used to efficiently generate MSCs that are highly proliferative, express MSG and pluripotency markers and undergo robust os!eo-, chondro- and adipogenesis. it has also been shown thai when incorporated info hydrogeis containing pentosan poiysu!phate in the form of HA-PPS, these iPSC-derived MSCs are stimulated to differentiate along the chondrogenic pathway, providing a first step in the process towards developing an effective MSC-based therapy for osteoarthritis. </p><p id="p0250" num="0250"> [00191] T e above description of various embodiments of the present invention is provided for purposes of description to one of ordinary skill in the related art. i t is not intended to be exhaustive or to limit the invention to a single disclosed embodiment. As mentioned above, numerous alternatives and 
<!-- EPO <DP n="48"/>-->
 variations to the present invention will be apparent to those skilled in the art of the above teaching. Accordingly, w ile some alternative embodiments have been discussed specifically, other embodiments will be apparent or relativel easily developed by those of ordinary skill in the art. Accordingly, this patent specification is intended to embrace aii alternatives, modifications and variations of the present invention that have been discussed herein, and other embodiments that fall within the spirit and scope of the above described invention. 
<!-- EPO <DP n="49"/>-->
</p><p id="p0251" num="0251">TABLES </p><p id="p0252" num="0252"><img id="imgf000049_0001" he="54" wi="119" file="imgf000049_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0253" num="0253"> Table 1 : Rheologicai characterisation oi PEG/HA hydroge s incorporating soluble PPS and HA - PPS. 
<!-- EPO <DP n="50"/>-->
</p><p id="p0254" num="0254">4S </p><p id="p0255" num="0255"> BIBLIOGRAPHY </p><p id="p0256" num="0256"> [1] Chen FH, Tuan S: Mesenchymal stem ceils in arthritic diseases. </p><p id="p0257" num="0257"> Arthritis Res 77ier 20G8, 0:223 </p><p id="p0258" num="0258"> [2] Spagnoli A, Longobardi L, O' ear L: Cartilage disorders: potential therapeutic use of mesenchymal stem cells. Endocr Dev 2005, S: 17-30. </p><p id="p0259" num="0259"> [3] Jorgensen C, Djouad F. Souffi C, Mrugaia D, Noel D: uitipotsnt mesenchymal stromal cells in articular diseases. Best Praci Res Ciin Rheumatol 2008, 22:289-284. </p><p id="p0260" num="0260"> [4| oth U, Steinert AF Tuan RS: Technology insight: adult mesenchymai stem cells for osteoarthritis therapy. Nat Ciin Praci Rheumatol 2008, 4:371-380. </p><p id="p0261" num="0261"> [5] Tuan RS, Boland G, lull R; Aduii mesenchymal stem cells and cell based tissue engineering. Arthritis Res Ther 2003, 5:32-45 </p><p id="p0262" num="0262"> [6] Shi S, Gronthos S: Perivascular niche of postnatai mesenchymal stem cells in human bone marrow and dental pulp. J Bone Miner RQS 2003, 18:696-704. </p><p id="p0263" num="0263"> [7] Gronthos S, McCarty R, Mrozik K, Fitter S, Paton S, Menicanin D, Itescu S, Bartoid PM, Xian C. Zannettino AC: Heat shock protein-90 beta (HspSOss) is expressed at the surface of mulfipotential mesenchymal precursor ceils (MPC): generation of a novel monoclonal antibody. STRO-4, with specificity for MFC from human and ovine tissues. Stem Cei!s Oev 2008, 18:1253-1282. </p><p id="p0264" num="0264"> |8] Ghosh P, Wu J, Shtmmon S, Zannettino A, Gronthos S, itescu S: </p><p id="p0265" num="0265"> Pentosan polysulfate promotes proliferation and chondrogenic differentiation of adult human bone marrow-derived mesenchymai precursor cells. Arthritis Research &amp; Therapy 2010. 12:R28 </p><p id="p0266" num="0266"> [9] Chen YS, RA Peiekanos, RL Ellis, R Home, EL Woivetang and N Fisk. </p><p id="p0267" num="0267"> (2012). Small molecule mesengenic induction of human induced pluiipotent stern cells to generate mesenchymal stem/stromai cells. Stem Cells Transnational Medicine 1 :83~95. 
</p></description><claims mxw-id="PCLM70078977" ref-ucid="WO-2014127418-A1" lang="EN" load-source="patent-office"><claim id="clm-0001" num="0001"><!-- EPO <DP n="51"/>--><claim-text/><claim-text>.CLAIMS </claim-text><claim-text> 1. A conjugate compound comprising hyaluronic acid, or a salt or derivative thereof, covalently bonded to pentosan poiysuifate, or a salt or derivative thereof. </claim-text><claim-text> 2. The conjugate compound of claim 1 or claim 2 wherein the conjugate compound is of formula HA-L-PPS wherein HA is hyaluronic acid, or a salt or derivative thereof, PPS is pentosan poiysuifate. or a salt or derivative thereof, and L is a linker unit having a first reactive group reactive with a first complimentary group on hyaluronic acid and further having a second reactive group reactive with a second complimentary group on pentosan poiysuifate.</claim-text><claim-text>3. The conjugate compound of ciaim 3 wherein the first reactive group of the Sinker unit is reactive with a carbonyl or hydroxy! functional group on hyaluronic acid. </claim-text><claim-text> 4. The conjugate compound of claim 3 wherein the second reactive group of the linker unit Is reactive with a cartooxylic acid group on pentosan poiysuifate. </claim-text><claim-text> 5. The conjugate compound of claim 3 wherein the first and second reactive group are selected from the group consisting of NH?, OH and SH.</claim-text><claim-text>6. The conjugate compound of claim 3 wherein L is formed from a diamine which reacts at the amine functionalities to bind to both HA and PPS, or derivatives thereof. </claim-text><claim-text> 7. The conjugate compound of claim 7 wherein the diamine is a CrC<sub>28</sub> aikyl diamine. </claim-text><claim-text> 8. The conjugate compound of any one of the preceding claims wherein the hyaluronic acid presents a functionality suitable for cross linking into a hydrogel.</claim-text><claim-text>9. The conjugate compound of any one of claim 2 to claim 8 wherein the conjugate compound is a conjugate compound of formula (I): 
<!-- EPO <DP n="52"/>-->
 
<img id="imgf000052_0001" he="60" wi="84" file="imgf000052_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 </claim-text><claim-text> Formula (I) </claim-text><claim-text> wherein, r^ is sufficient to provide a molecular weight of between 1 ,000 to 20,000 daitons for the pentosan poiysuifate component of the conjugate and ri2 is sufficient to provide a molecular weight of between 5,000 to 20,000,000 daitons for the hyaluronic acid component of the conjugate; </claim-text><claim-text> each X is independently a salt forming ion selected from the group consisting of sodium, calcium, magnesium and potassium ions or X may be selected from hydrogen, af<sup>'</sup>kyi, alkenyi, carboxyl, aikanoyt aikanoyioxy and carboa!koxy; </claim-text><claim-text> each i group is independently selected iron's a salt forming ion, hydrogen, alkyl, alkenyi, aryiaikyl, hydroxyalkyt, aldehyde, alkanone, carboxyl, carboxa nide, a!kanoyi, carboalkoxy, carboaryloxy, carbonate, O-afkyf, O-aryl, G-alkenyl, O-alkanoyl and Oaikenoyl; and </claim-text><claim-text> L is as previously defined. </claim-text><claim-text> 10. The conjugate compound of any one of claim 2 to claim 0 wherein L Is formed from !¾ which is selected from the group consisting of alkyl, aminoalky!, diaminoalkyl, acyi and ether each of which may contain one or more further heteroatoms selected from sulphur, oxygen and nitrogen. 
<!-- EPO <DP n="53"/>-->
</claim-text><claim-text>1 1 . The conjugate compound of claim 9 wherein rii is sufficient to provide a molecular weight of between 2000 to 10,000 daitons for the pentosan poiysuifaie component of the conjugate compound. </claim-text><claim-text> 12. The conjugate compound of ciaim 9 wherein n<sub>a</sub> is sufficient to provide a mo!ecuiar weight of between 50,000 daitons to 2,000,000 daitons for the hyaluronic acid component of the conjugate. </claim-text><claim-text> 13. The conjugate compound of any one of claim § to ciaim 12 wherein the conjugate com ound of formula (!) is a conjugate compound of formula (H): </claim-text><claim-text><img id="imgf000053_0001" he="60" wi="83" file="imgf000053_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></claim-text><claim-text> Formuia 0!) wherein X, R-. , n-t and n<sub>2</sub> are as previously defined and wherein,</claim-text><claim-text>R is seieeted from the group consisting of alkyi, disufphide, aiky!disuSpnide, acyi, ether, car oaikoxy and a!kanoytaxy. </claim-text><claim-text> 14. The conjugate compound of any one of claim 9 to claim 13 wherein the conjugate compound of formuia (I) or (SI) is a conjugate compound of formuia (Ul), or a salt thereof: 
<!-- EPO <DP n="54"/>-->
</claim-text><claim-text><img id="imgf000054_0001" he="63" wi="83" file="imgf000054_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></claim-text><claim-text> Formula (ill) </claim-text><claim-text> wherein n-j and ¾ and X are as previously defined. </claim-text><claim-text> 15. The conjugate compound of daim 14 wherein X is sodium, </claim-text><claim-text> 6. The conjugat compound of any one of daim 9 to daim 13 wherein the conjugate compound of formuia (!) or (IS) is a conjugate compound of formula (Hia), or a salt thereof: </claim-text><claim-text><img id="imgf000054_0002" he="63" wi="95" file="imgf000054_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></claim-text><claim-text> wherein π&lt; and n<sub>2</sub> are as previously defined. 
<!-- EPO <DP n="55"/>-->
</claim-text><claim-text>17. A method of synthesislng a conjugate compound including the step of coupling hyaluronic acid., or a derivative thereof, to pentosan poiysuifate, or a derivative thereof, via a covalent bond, </claim-text><claim-text> 18. The method of claim 1 ? wherein the hyaluronic acid and/or pentosan polysuiphate, or a salt or derivative thereof, are first chemically modified to present a linker unit prior to covalent bonding. </claim-text><claim-text> 19. The method of claim 18 wherein the hyaluronic: acid, or salt or derivative thereof, ss chemically modified to present a linker group having a primary amine functionality. </claim-text><claim-text> 20. The method of claim 19 wherein the linker group having a primary amine functionality is generated on the hyaluronic acid b reaction thereof with a diamine compound. </claim-text><claim-text> 21. The method of claim 19 wherein the chemical modification of the hyaluronic acid, or salt or derivative thereof, is performed via a carboxy! group activation pathway using a carboxy! activating group. </claim-text><claim-text> 22. The method of claim 19 wherein the primary amine of the hyaluronic acid linker group Is reacted with a carboxy! group on the pentosan poiysuifate, or salt or derivative thereof. </claim-text><claim-text> 23. The method of any one of claim 17 to claim 22 wherein the hyaluronic acid is modified to present a group reactive with a functionality on a polymer to allow for incorporation into a polymer matrix. </claim-text><claim-text> 24. The method of claim 23 wherein the modification involves reaction of the hyaluronic acid with tyramine. </claim-text><claim-text> 25. A conjugate compound of hyaluronic acid <sub>s</sub> or a salt or derivative thereof, covaientfy bonded to pentosan poiysuif ate, or a salt or derivative thereof when produced by the method of any one of claim 17 to claim 24, </claim-text><claim-text> 26. A pharmaceutical composition comprising an effective amount of a conjugate compound of any one of claim 1 to claim 16 and a pharmaceutically acceptable carrier, diluent and/or exciplenf. 
<!-- EPO <DP n="56"/>-->
</claim-text><claim-text>27. The composition of claim 26 further comprising a pluripoteni or muitipotent stem ce!! population. </claim-text><claim-text> 28. The composition of claim 27 comprising a polymeric matrix within which the conjugate compound and stem ceil population are captured. </claim-text><claim-text> 29. The composition of claim 28 wherein the polymeric matrix is a hydrogef.</claim-text><claim-text>30. The composition of any one of claim 26 to claim 29 comprising a further additive selected from the group consisting of giycosaminoglycan (GAG), unbound hyaluronic acid (HA), chondroitin sulphate, dermatan sulphate, keratin sulphate, heparin, heparin sulphate and unbound PPS. </claim-text><claim-text> 31 . The composition of any one of claim 26 to claim 29 further comprising osteogenic promoting factors and/or supplements. </claim-text><claim-text> 32. A method of treating or preventing a disease, disorder or condition responsive to connective tissue repair and/or maintenance in a patient including the step of administering an effective amount of the conjugate compound of any one of claim 1 to claim 18 and a p!uripoterrt or muitipotent stem ceil population, amSiOr progeny cells thereof, to the affected or potentially affected tissue.</claim-text><claim-text>33. The method of claim 32 wherein the disease, disorder or condition is connective tissue degeneration, </claim-text><claim-text> 34. The method of claim 32 wherein the affected tissue is an intervertebral disc, a cartilaginous structure or bone tissue. </claim-text><claim-text> 35. The method of any one of claim 32 to claim 34 wherein the conjugate compound and stem cell population are co-administered. </claim-text><claim-text> 36. The method of claim 35 wherein the conjugate compound and stem cell population are administered within a polymeric matrix. </claim-text><claim-text> 37. The method of claim 38 wherein the polymer matrix is inserted in or near the affected or potentially affected tissue to function as a physical support.</claim-text><claim-text>38. The method of any one of claim 32 to claim 37 wherein the muitipotent stem ceil population is selected from the group consisting of mesechymal 
<!-- EPO <DP n="57"/>-->
 58 </claim-text><claim-text>precursor cells (MPCs), dental pulp stern cells (DPSCs) and periodontal ligament stem ceils (PDLSCs). </claim-text><claim-text> 39. The method of ciairn 38 wherein the MPCs are obtained or are obtainable from human bone marrow. </claim-text><claim-text> 40. The method of any one of claim 32 to claim 39 further comprising administering an additive selected from the group consisting of glycosaminogf can (GAG), unbound hyaluronic acid (HA), chondroitin sulphate, derniatan sulphate, keratin sulphate, heparin, heparin sulphate arid unbound PPS. </claim-text><claim-text> 4 . The method of any one of claim 32 to claim 40 wherein administration of the conjugate compound and stem cell population causes chondrogenic differentiation of the stem cells as measured by increased glycosaminogiycan (GAG) production. </claim-text><claim-text> 42. A conjugate compound of any one of claim 1 to claim 16, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of a disease, disorcseror condition responsive to connective tissue repair and/or maintenance in a patient. </claim-text><claim-text> 43. The use of claim 42 wherein the disease, disorder or condition Is connective tissue degeneration. </claim-text><claim-text> 44. The use of claim 42 wherein the effected tissue is an intervertebral disc, a cartilaginous structure or bone tissue. </claim-text><claim-text> 45. The use of any one of claim 42 to claim 44 wherein the conjugate compound Is administered with a piuripotent or muitjpotent stem cell population.</claim-text><claim-text>46. The use of claim 45 wherein the conjugate compound and stem cell population are administered within a polymeric matrix. </claim-text><claim-text> 47. The use of any one of claim 45 wherein the mu!tipotent stem ceil population s selected from the group consisting of mesechymai precursor cells (MPCs), denial pulp stem cells (DPSCs) and periodontal ligament stem cells (PDLSCs). 
<!-- EPO <DP n="58"/>-->
</claim-text><claim-text>48. The use of claim 47 wherein the MFCs are obtained or are obtainable from human bone marrow. </claim-text><claim-text> 49. The use of any one of claim 42 to claim 48 further comprising administering an additive selected from the group consisting of gtyccsaminoglycan (GAG), unbound hyaiuronic acid (HA), chondrostin suiphate, dermatan suiphate, keratin sulphate, heparin, heparin suiphate and unbound PPS. </claim-text><claim-text> 50. A method of enhancing, promoting or maintaining the chondrcgenic potential of a stem cell including the step of contacting the stem ceii with a conjugate compound of any one of claim 1 to claim 18. </claim-text><claim-text> 51. A method of reducing or inhibiting the osteogenic differentiation of a stern cell including the step of contacting the stem ceil with a conjugate compound of any one of claim 1 to claim 16. 
</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
